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CHAPTER 1
INTRODUCTION

According to the World Heart Organization, cardiovascular diseases claim 17.1
million lives each year, from which congenital heart defects account for 26%. As the
most frequent congenital anomaly and the leading cause of death, congenital heart
disease is an attractive target for tissue engineering research [1]. New drugs and
innovative devices have improved the quality of life for pediatric patients with congenital
heart defects, but have not necessarily decreased the morbidity and mortality.

The

incidence of moderate or severe form of cardiovascular heart defects is about 6/1000 live
births [2, 3].
The challenging target to engineer a native blood vessel stems from the need to
find substitutes for pediatric patients born with congenital defects. With the advances in
the fields of biomaterials and tissue engineering, scientists have been exploring the use
of synthetic non-degradable, synthetic resorbable, natural polymers and completely cell
based approach. Some of the approaches take advantage of materials such as collagen
or use of natural components in synthetic materials.
One promising alternative involves using a tissue-engineered graft. The tissue
engineering graft functions to bring various cells of the vasculature in close proximity to
one another to enable intercellular signaling which facilitates cell adhesion, migration and
differentiation [4]. Using the classical tissue-engineering paradigm (figure 1.1),
autologous cells are seeded on a tubular scaffold, which provides surfaces for cell
attachment and space for neotissue formation [1, 5, 6]. The ideal graft requires a range

2
of characteristics including strength, biocompatibility, biostability and ability to adapt to
the hemodynamic conditions in the short and long term.

Figure 1.1 Concept of Tissue Engineering.

The current approaches take advantage of materials like collagen, alone or with the use
of natural or synthetic material to create hybrid constructs. The pros and cons of these
vascular grafts were determined by the long-term biocompatibility and mechanical
properties of the replacement graft.
In the case of non-degradable synthetic polymers, long-term biocompatibility of
the material and tissue integration is low. Researchers have attempted to address this
issue by altering the porosity of the materials, as well as integrating bioactive materials
like collagen and or gelatin [7]. Synthetic vascular grafts such as Dacron (PET) and
ePTFE (expanded polyethylene terepthalate) are the commonly commercial used
vascular graft replacements. These grafts are not suitable for pediatric patients since
they lack the capacity to grow with the patient, are prone to platelet adhesion and
inflammatory reaction and lack adequate cell migration.
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The overall goal of this project was the development of an artificial vascular graft
using a tissue-engineering approach as well as in-vitro 3-D culture. This work was
structured into the following eight chapters:
I.

Introduction

II.

Physiological Background

III.

Proposal for a Tissue Engineered Vascular Graft

IV.

Cell Isolation and Cell Biomaterials interaction Studies

V.

Scaffold Fabrication and Seeding

VI.

Bioreactor Design, Fabrication and Culture

VII.

Overall Conclusions and Future Directions

VIII.

References
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CHAPTER 2
PHYSIOLOGICAL BACKGROUND

2.1 GENERAL BLOOD VESSEL ANATOMY
The vascular system’s function is to transport blood to all organs and tissues in
the body. Blood vessels have a great degree of variability and sizes, mechanical
properties and biological function. In this integrated system, the aorta is the largest
artery in the body, which rises from the heart’s major pumping chamber, the left ventricle.
From the left ventricle of the heart, oxygen-rich blood enters the body through the aorta
[8]. Subsequently, the aorta dampens the pulsatile pressure that results from the
sporadic ejection of blood from the ventricle and travels throughout the body through the
small arteries branching from it.
Both the aorta and other large blood vessels near the heart have connective fibers
within the aortic wall. These fibers allow the wall to stretch as it experiences pressure
and then return it to the relaxed state as the pressure drops. The essential elastic
component of the aorta gives it acceptable properties to deal with the high pressure and
flow.
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Figure 2.1 Structure of Aorta (http://www.csmc.edu/.html)

The aorta is comprised of aortic root, ascending aorta, aortic arch, descending
aorta, thoracoabdominal aorta and abdominal aorta. The aortic root is the start of the
aorta. It starts from the aortic valve and branches into two coronary arteries at the
beginning of ascending aorta. Their function is to transport oxygen-rich blood to the heart
muscle. The ascending aorta starts from the upper part of the base of the left ventricle
and passes diagonally upward, forward and to the right in the direction of the heart axes
and no arteries branch from it. There is no support from the surrounding tissue;
therefore, the ascending aorta has to withstand the entire cardiac output volume. The
aortic arch characterizes the curved section of the aorta. The descending aorta starts
below the arch and curves down through the body and ends at the diaphragm. This aorta
has intercostal arteries that nourish the spinal cord. The thoracoabdominal aorta is the
part of the aorta between the diaphragm and visceral vessels. The last part of the aorta
begins at the renal arteries that supply blood to the kidneys and ends when it divides in
two iliac arteries [9].
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The aortic wall is composed of three separate layers as seen in Figure 2.2. The
outer layer (tunica adventitia) consists of connective tissue. The layer provides rigidity to
blood vessels anchors them to the surrounding tissues and helps in maintaining their
shape. The middle layer (tunica media) is made of smooth muscle cells, elastic fibers
and connective tissue [10]. The middle layer is separated from the adventitia by a thick
elastic layer called the external elastic lamina. The extracellular components found
between smooth muscle cells aid in minimizing energy loss during the pressure changes.
The inner layer (tunica intima) is composed of a film of endothelial cells bonded by a
polysaccharide matrix. This layer is separated from the media by an internal elastic layer.
Smooth muscle cells then migrate from the medium layer in the inner layer and form
contacts with endothelial cells by fenestrae that interrupt the internal elastic lamina.
Since, the diffusion of oxygen from the intima to the adventitia is insufficient, capillary
vessels and small arterioles start in adventitia and have vascular branches in the other
half of the media [5, 11].
Each layer has a definite function and specific cell types. The intimal layer
consists of endothelial cells while the tunica media consists of smooth muscle cells
embedded in extracellular matrix (ECM) components including collagen, elastin fibers
and proteoglycans. The ECM interacts with vascular cells to regulate their adhesion as
well as proliferation and provides the mechanical integrity of the blood vessel. It is the
natural scaffold for tissues with a dynamic and complex structure, provides signals for
cell proliferation and differentiation, promotes maintenance of differentiated tissues and
enhances repair response after injuries. The surface chemistry of ECM decides which
proteins present in the serum are adsorbed to the matrix [12-14]. Elastin is one of the
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main components of ECM, which provides the elasticity of the vessel. The elastic fibers
separate the intima from the media and the layers of smooth muscle cells are connected
radially to withstand the stress due to flow throughout the vessel wall.
The tunica adventitia consists of fibroblasts, which are part of the connective
tissue [5].

While the endothelial layer forms a membrane inside the aorta, it helps

transport small and large molecules throughout the arterial wall. The smooth muscle
cells present in the intimal layer perform functions such as vasoconstriction, dilation and
synthesis of various types of collagen, elastin and proteoglycans. The intimal layer of the
blood vessel contains high amount of proteoglycans and hyaluronan, which gives blood
vessels their viscoelastic and compressible characteristics, whereas the adventitia has a
high content of collagen leading to a rigid attribute.

Intima

Media

Adventitia

Figure 2.1 Architecture of the Blood Vessel Anatomy
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The organization and physiology of these three layers of the blood vessel were
considered in order to design an artificial vascular graft that has in-vivo long-term
biocompatibility and compliance.

2.2 CONGENITAL BIRTH DEFECTS
Congenital birth defects are structural abnormalities of the heart or intrathoracic
great vessels that occur during pregnancy. The overall incidence is 8.14/1000 total births
and only some have a known genetic cause [15]. Most serious congenital birth defects
are diagnosed during infancy.

2.2.1 Arteriovenus malformation
Arteriovenous malformation occurs due to an abnormal connection between veins
and arteries, which generally occurs at embryonic and fetal development at birth. The
defect results in a tangling of the blood vessels with no capillaries and abnormal direct
connections between high-pressure arteries and nutrients to the cells. The most common
symptoms of arteriovenus malformation include hemorrhaging, headaches and
neurological problems such as loss of speech, memory or vision. The treatment for this
disease depends on the complexity of the malformation. Endovascular occlusion
involves closing off vessels and radiosurgery, which involves focusing multiple radiation
beams to stop the clog. The best-known treatment is surgery, which means identifying
the margins of the malformations, clipping the feeder and obliterating the draining veins
and removing the nodules.
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2.2.2 Pulmonary Artery Stenosis
Pulmonary artery stenosis occurs when the pulmonary artery is narrowed or
constricted. This defect restricts flow of blood to lungs and blood pressure increases to
overcome the lack of oxygen but as a result, the heat muscle experiences severe
damage [16] .
Clinical symptoms of this disease include shortness of breath, fatigue, heavy
breathing, rapid heart rate and swelling of feet, eyelids, abdomen and ankles. The
condition usually goes undetected if the child does not experience at least 50 % of the
symptoms. The treatment for this disease depends on the symptoms as well as the
severity of the stenosis. The initial treatment involves balloon dilation in which a catheter
is inserted into the narrowed area of the artery until the area is widened. Stent
replacement was used in the addition with balloon angioplasty [17, 18]. The stent is
placed in the area where it as expanded. The last treatment used for artery stenosis is
surgery in which the portion of the affected artery is removed.

Figure 2.3 Pulmonary Stenosis
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2.2.3 Truncus Arteriosus
Truncus arteriosus is a rare congenital disease in which a single blood vessel
comes out of the right and left ventricles, instead of two forms both the aorta and
pulmonary artery as seen in Figure 2.5. It accounts for 0.7 % of all complex heart lesions
[19-21]. The pediatric patients with this disease risk an infection to the heart valves. If left
untreated problems can occur such as (a) increase blood circulation in the lungs, which
causes extra fluid to build up and make it difficult to breathe; (b) blood vessels become
permanently damaged over time causing hypertension. Clinical symptoms include
cyanosis, delayed growth, fatigue, lethargy, rapid breathing, and shortness of breath and
widening of the fingertips. The definitive treatment is in general surgery, in which
pulmonary artery is disconnected from the large common artery. Delay of the operation
can result in chronic ischemia of the hypertrophied ventricle, which is perfused by the
desaturated blood at low diastolic perfusion pressure caused by the runoff through the
pulmonary arteries. The pulmonary artery is connected to the ventricle using a tube graft
[22-30] .

(a)

(b)

Figure 2.4 Truncus Arteriosus (a) Before repair; (b) After repair
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CHAPTER 3
PROPOSAL FOR A TISSUE ENGINEERED VASCULAR GRAFT

The long-term goal of this work was the development of methods for generating
transplantable vascular tissue for pediatric applications. We suggest that this
biodegradable vascular substitute will provide with the possibility of application on large
vessel diameter prosthetic grafts in artificial blood vessels. Infants who have congenital
disease such as truncus arteriosus undergo multiple interventions; hence, a biological
graft would be a good replacement and would eliminate the use of surgery as the infant
grows. The graft will grow with the infant, which would eliminate the infant having
multiple surgeries. Our long-term objective is to fabricate a polysaccharide based
vascular graft based on the use of chitosan, for the development of a large vascular graft
for pediatric applications. Chitosan is biodegradable, biocompatible and biologically
active which would not spawn any detrimental inflammatory responses.
In this work, we compared the effects of glycosaminoglycans (GAG) and a GAGlike polyanion as modifiers of smooth muscle and endothelial cells activity. We also
investigated various scaffold formulations and seeding techniques for enhanced cellular
entrapment and high cell proliferation. In-vitro, 3D scaffold cultures under non-pulsatile
and pulsatile flow conditions were explored to generate vascular grafts with appropriate
cellular alignment and tissue generation.
We explored the prospect of a tissue engineered large vessel graft using
polysaccharide biomaterials, which would be conditioned in a 3D environment similar to
the physiological conditions.
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3.1 HYPOTHESES
The overall hypotheses are:
I.

Incorporation of glycosaminoglycans (GAG) into a chitosan scaffold will enhance
cell adhesion and extracellular matrix production.

II.

Incorporation of collagen (bulk or gel), and GAG into chitosan will facilitate cellular
entrapment, proliferation, organization and matrix deposition.

III.

A 3D perfusion bioreactor environment for cell conditioning will facilitate long-term
functionality, cell distribution, and proliferation, viability of cells in the construct
and ECM production.

3.2 SPECIFIC AIMS
The objectives of the present study were to explore the use of chitosan cross-linked
with GAG for developing a vascular graft. In-vitro culture under pulsatile conditions was
considered as the best 3D environment for cellular alignment, proliferation and tissue
creation. The specific aims of the project include:

I.

Assess the growth, proliferation, adhesion, and spreading of SMCs and ECs on
covalently immobilized GAG-chitosan and GAG-chitosan/collagen in-vitro. This
would allow us to determine the best GAG-material composition on which
vascular cells would proliferate.
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II.

Create highly porous GAG-chitosan scaffold with specific structure and
demonstrate its efficiency in homogenous seeding. This porous structure will allow
to trap and culture smooth muscle cells as well as endothelial cells.

III.

Design and evaluate a pulsatile bioreactor system for long-term 3D culture of
large diameter tissue engineered constructs with efficient cell seeding, cell
distribution and viability. Besides providing nutrients and proper gas flow to the
vascular graft, this pulsatile system is expected to improve smooth muscle cell
alignment in the circumferential direction.
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CHAPTER 4
Evaluation of Smooth Muscle Cell and Endothelial Cell
Proliferation on Polysaccharide-Based Materials

4.1. INTRODUCTION
Proteoglycans are macromolecules composed of glycosaminoglycans
chains covalently linked to a protein core and are one of the major components in
extracellular matrix (ECM) of native tissue. The biological roles of proteoglycans are
highly diversified ranging from cell adhesion, proliferation, and motility to differentiation
and tissue morphogenesis. Their roles depends on the binding of proteins to the
glycosaminoglycans (GAG) chains that in turn can form interactions with extracellular
matrix, growth factors and cell surface receptors. GAGs have direct receptor interactions,
which stimulate intracellular signal transduction pathways that lead to cellular responses
such as proliferation, differentiation or cell death [31]. The GAGs are water-soluble and
are usually obtained as salts of sodium, potassium or ammonia and in this form. The
presence of strongly ionized sulfate groups indicates that the charge densities of these
molecules are not pH dependent as in the case of chitosan. Therefore, these materials
are soluble in water over a wide pH range.
While the use of extracellular matrix proteins and peptides as scaffold
components has been widely studied, more complex combinations of polymers with
ECM proteins and glycosaminoglycans have not been largely explored. Most ECM
proteins have at least one GAG binding domain, and the GAG-protein interactions may
serve to facilitate the aggregation and organization of matrix proteins into ordered
structures. At the same time, combining chitosan’s structural properties with GAG
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biological activity in a covalent complex may produce biomaterials that have superior
potential. Such multi component combinations may more effectively mimic the physical
and biological activity of the native tissue matrix, possibly leading to a faster attainment
of a more fully functional regenerated tissue.

4.2. SPECIFIC AIMS
In this part of the project, the working hypothesis was that enhanced protein absorption
mediated by immobilized GAGs, combined with the presence of collagen would improve
proliferation, adhesion, and spreading of smooth muscle cells and endothelial cells. In an
attempt to test this hypothesis, the specific aim 1 was to explore the effects on vascular
cells of two and three component biomaterials composed of chitosan or collagenchitosan blends covalently derivatized at various levels with various GAGs with a view
towards developing an improved tissue engineered vascular prosthesis.

4.3. BACKGROUND
4.3.1 Biomaterials
Chitosan
Chitosan is a linear cationic natural biopolymer produced by alkaline N-deacetylation
of chitin [32-36], the structural polysaccharide found in the cell walls of certain fungi and
the exoskeletons of arthropods. The structural polysaccharide found in the cell walls of
certain fungi and the exoskeletons of arthropods. Chitosan is a biodegradable and
bioresorbable polymer vulnerable to enzymes like chitobiases, glucosaminidases, and Nacetyl-glucoasminidases [37-39]. It is a crystalline polysaccharides and the degree of
crystallinity is a function of the extent of deacetylation. It is a copolymer of 2-acetamido-
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2-deoxy-β-D-glucopyranose (GlcNAc) and 2-amino-2-deoxy-β-D-glucopyranose (GlcN),
where the content of GlcN is more than 75% [33, 40].

NHCOCH3

HOH2C
R1

O
O
OH

HO
O
O

NH2

CH2OH

R2
n

Figure 4.1 Structure of chitosan

It presents a wide selection of mechanical properties depending on the molecular
weight, degree of deacetylation and molecular architecture. To control its degree of
degradability, the degree of deacetylation is varied. The degradation of chitosan plays a
key role in long term performance of the tissue engineered construct [41]. Water content,
molecular architecture, the shape and state of the surface are some other factors that
affects it’s degradability [42].
Chitosan does not bring out any inflammatory or allergic reaction following
implantation, injection or ingestion under normal circumstances, but releases amino
sugars on degradation, which get incorporated in different metabolic pathways [43].
Molecular modifications of chitosan such as blending and cross-linking techniques alter
the mechanical behavior, degradation and cell surface response [44-46].
The existence of a cationic group in chitosan directs electrostatic interactions with
anionic cell membranes leading to cell attachment, growth, proliferation and bioactive
property of chitosan. This is due to the presence of either the cationic groups or the
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GlcNAc units. The presence of GlcNAc units leads to production of NO by macrophages
[47-49].
Various properties of chitosan are appealing; it has possible usage in diverse
biological implants. Much of the chitosan’s biomaterial potential is due to the cationic
nature and high charge density in solution. Abundant efforts have been and are currently
being made in order to manage its solubility, biocompatibility, mechanical properties,
hydrophobicity, water uptake [44, 50, 51] for using its potential to the fullest. It has been
observed that chitosan can be molded into a range of porous structures by freeze-drying
technique [52]. All these factors synergistically make it a potential candidate for a variety
of tissue engineering applications.

Collagen
Collagen is a structural protein and the most plentiful constituent in the
mammalian connective tissue accounting for 90% of the proteins of the human body
(Figure

4.2).

In vivo,

collagen is

often

associated

with

extracellular matrix

polysaccharides such as GAGs. The connection between collagen and GAG is
interceded by both covalent and electrostatic linkages. Collagen distinguishes itself by a
unique triple-helix formation extending over a large fraction of the molecule. The stability
of the collagen was attributed to the proline and glycine residues found in the chains. Invitro, individual collagen molecules will polymerize into strong fibers, which form
intermolecular and intramolecular cross-links to form tissues [53-55].
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Figure 4.2 Collagen (a) chemical Structure; (b) quaternary structure; (c) triple helix structure; (d)
fibril structure [56].

Tensile stress and intermolecular cross-links increase when the biodegradation
rate amplifies as the capacity of collagen to absorb water. Collagen and its integrin
binding domains assist in cell attachment, growth, differentiation and metabolic activity.
The collagen matrices have mechanical strength both wet and dry.

Glycosaminoglycans
Glycosaminoglycans (GAGs) are highly sulfated polysaccharides, which naturally
occur as side chains to a protein chain, that form an important component of extracellular
matrices [57] and are present on the surfaces of all adherent animal cells. They have an
important role in cell growth, migration and differentiation during development, then
throughout the adult life.
GAGs are long unbranched polysaccharide chains of repeating disaccharides
units, which are composed of one amino sugar and one uronic acid. Sugar units are
linked by α- or β- 1, 3, or 1, 4 glycosidic bonds. They are

negatively charged
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macromolecules can be immobilized due to the presence of sulfate and/or carboxyl
groups in their repeating units on different surfaces like nitrocellulose membranes [58],
polylactic acid-co-glycolic acid (PLGA) surfaces [59] and on chitosan scaffolds [60] which
modulate growth factor activities.
Proteoglycans operate as tissue organizers, influence cell growth and the
maturation of specialized tissues. The specific types of polysaccharides attached to
proteoglycans are called glycosaminoglycans (GAGs). The most common GAGs include
chondroitin sulfate (CS), dermatan sulfate (DS), heparin (HE), keratan sulfate and
heparan sulfate (HS). Dermatan sulfate, heparin sulfate and heparin contain GIcA (Dglucuronic acid) and IdoA (L-iduronic acid) units, whereas CS has GlcA as the only
hexuronic part.
Heparin (HE) is the sulfated GAG with the highest charge density. It is made of
repeating L-iduronic acid and N-acetyl-D-glucosamine disaccharide units. It is primarily
found in mast cells lining the arteries of the lungs and in liver and skin. It has a molecular
weight ranging from 10 - 12 kDa. Since charge density has been shown to be directly
proportional to the binding efficiency [61] , the high charge density of heparin enables it
to more efficiently bind to various growth factors. It was the first GAG known for its
biological function. Heparin is used extensively as a clinical anticoagulant.
Heparan Sulfate (HS) is also a highly sulfated GAG consisting of repeating Dglucoronic acid and N-acetyl-D-glucosamine disaccharide units. It is mainly of
component on cell surfaces, also found in the arterial wall and lungs. It has a molecular
weight ranging from 25 – 100 kDa. It is emphasized as the most biologically active GAG
[62-64].
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Chondroitin Sulfate (CS) is the most abundant GAG found in the body and is the
most important structural component of cartilage. It consists of repeating D-glucuronic
acid and N-acetyl-D-galactosamine disaccharide units. It has a molecular weight ranging
from 20 – 30 kDa. It is mainly found in the cartilage, bone and heart valves. Based on the
site of sulfation, it is classified into chondroitin Sulfate A, C, D and E. It is used
extensively as a dietary supplement in the treatment of osteoarthritis.
Dermatan Sulfate (DS), also known as chondroitin sulfate B, comprises of
repeating uronic acid and N-acetyl-D-galactosamine disaccharide units. It has a
molecular weight ranging from 28 – 32 kDa. This is mostly found in skin, blood vessels
and heart valves. It has been reported to find application in the treatment of
cardiovascular diseases, wound repair and fibrosis [65].
Keratan sulfate (KS) is composed of repeating D-galactose and N-acetyl-Dglucosamine disaccharide units. It has a molecular weight ranging from 3 – 20 kDa. This
is primarily found in cornea, bone and cartilage.

Heparin and Heparan
Sulfate

Chondroitin Sulfate A

Dermatan Sulfate

Figure 4.3 Glycosaminoglycan’s chemical structure
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Conventionally, the interactions of the GAG with proteins and cells are studied
with GAGs in solution but the 3-dimensional interactions between the immobilized GAGs
and proteins are different from those observed in solution. Hence, the hypothesis to use
immobilized GAG to mimic the in vivo environment. It has been shown that covalent
immobilization is more important over ionic immobilization during in vitro studies [45].
The covalent immobilization incorporates the biologically active GAGs in scaffolds for
tissue applications.
GAG may be easily immobilized on chitosan either ionically or covalently. The
covalent immobilization can be achieved by the formation of an amide bond between
carboxyl group in the GAG and chitosan amino group using the zero cross linker EDC
according to the reaction scheme shown in Figure 4.4.

Figure 4.4 Amine bon

Figure 4.4 Covalent GAG immobilization onto chitosan by carbodiimide chemistry [66]
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4.3.2 Cell Source
There are mainly two types of cells needed for a tissue engineered vascular graft:
smooth muscle cells (SMC) that make up the bulk of the construct and endothelial cells
which are needed to provide the thromboresistant coating of the lumen and to allow
specific permeability [14]. Researchers have explored two types of cell sources, which
are terminally differentiated cells and progenitor cells.

Terminally Differentiated Cells vs. Progenitor Cells
Terminally differentiated cells are cells with the desired phenotype, isolated,
cultured and expanded to the number required [14]. The foremost benefit of using
terminally differentiated cells is that they have the same cellular elements of the native
artery but large amounts of cells are needed and the isolation requires an invasive
procedure. However, for current studies, these terminally differentiated smooth muscle
and endothelial cells are used.
Progenitor cells are undifferentiated cells commonly from bone marrow sources.
These cells are easy to obtain from a patient and can be sorted by density and marker
expression. However, the main disadvantage is that factors that contribute for
differentiation of progenitor cells into smooth muscle and endothelial cells are not yet
understood.

Smooth Muscle Cells
Vascular smooth muscle cells (SMC) represent an essential component of the
aorta [10, 67]. SMC are involved in collagen, elastin and proteoglycans synthesis and
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contractile activities [68, 69]. Resting vascular smooth muscle cells have a spindle shape
with single, elongated nuclei resembling fibroblasts where contractile smooth muscle
cells have their function mediated by actin and myosin filaments. Smooth muscle cells
are able to express a range of phenotypes due to the cell-cell interactions and alterations
of extracellular matrix. At one end is the contractile phenotype, which has reduced
proliferation and occurs mainly in development, repair and pathological conditions.
At the other end of the spectrum, is the synthetic phenotype, when the cells
proliferate, migrate and actively produce extracellular matrix proteins. In synthetic
phenotype there is a decreased expression of contractile and adhesion proteins with an
increase in cytoskeleton proteins [70, 71]. SMC synthesize fourfold the amount of
collagen and fivefold the amount of sulfated glycosaminoglycans in comparison to the
contractile state.

Endothelial Cells
Endothelial cells are the cells that form the inner lining of the aorta. Endothelial
cell structure and functional reliability are essential in maintaining the vessel wall and the
circulatory function. They form a confluent monolayer with a cobblestone shape. Under
flow conditions, endothelial cells orient in the direction of the flow. Endothelial cells
functions include response to and secretion of prostaglandins, angiotensins, adrenaline,
control of vascular tone, secretion of growth factors for neovascularization, control of
smooth muscle cells, and regulation of coagulation, perfusion and permeability in
microcirculation. Endothelial cells also play a role in homeostasis, fibrinolysis,
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coagulation, vasotone regulation, growth regulation and migration during physiological
and pathological processes [72-74].

4.4. EXPERIMENTAL WORK
4.4.1 Materials
Rat-tail collagen, type I was isolated from rat-tails and prepared in house [75].
GAGs used in this study includes heparin from porcine intestinal mucosa (MW 15,000
g/mol) purchased from Celsus Laboratories (Cincinnati, OH). Dextran sulfate (MW
40,000 g/mol) was purchased from Carbomer, Inc (San Diego, California). The stains
rhodamine phallodin and DiI-labeled-Ac-LDL was purchased from Invitrogen and
Safranin-O dye was purchased from EM Science (Gibbstown, NJ). All other reagents
were obtained from Sigma (St. Louis, MO).

4.4.2 Methods
4.4.2.1 Aortic Endothelial Cell Isolation and Culture
Aortas tissue from adult pigs was obtained from the Countryside Quality Meats
slaughterhouse (Union City, MI). The aortas were stored in HBSS until isolation. Prior to
removing any tissue, the aorta was washed several times with 1X phosphate buffer
solution enhanced with 1% streptomycin. After the fat tissue was manually stripped from
the aorta and the vessel was rinsed with 1X phosphate buffered saline (PBS). The ends
of the aorta were ligated and the vessel lumen was filled by injecting warm (37°C) Krebs
Ringer Bicarbonate buffer containing 600 U/ml of type IV collagenase. Any excess
collagenase was rinsed from the exterior of the vessel with PBS to prevent digestion of
adventitial tissue [76, 77]. The aorta was transferred into a 300 ml beaker filled with
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phosphate saline buffer and incubated at 37ºC. After 45 minutes, the aorta was cut
longitudinally and the collagenase solution with suspended endothelial cells was
transferred to a 50 ml tube. The aorta was then scraped with a stainless steel blade
inclined at 60 º to the intimal surface. The supernatant was discarded and the white
pellets of endothelial cells were resuspended in 5 ml of culture medium. Then the
endothelial cells were suspended in DMEM supplemented with 1% penicillinstreptomycin, 15% fetal bovine serum, and 50 µg/l gentamycin. Endothelial cells were
seeded at 5000 cells/cm2 density on tissue culture plates and incubated at 37ºC in 95%
air/ 5% CO2 incubator. Porcine aortic endothelial cells attach within 24 hours and were
subcultured when they reach 80% confluence.

Subculture was achieved by using

trypsin-EDTA .Single cell suspensions were obtained by storing the plate at 37ºC for 4
min .Cells were counted in a haemocytometer and viability was assessed

with 1%

trypan blue . Endothelial cells from passages 1 to 3 were frozen and stored in liquid
nitrogen for future experiments.

4.4.2.2 Aortic Smooth Muscle Cell Isolation and Culture
After removal of endothelial cells, the aorta was washed again with additional PBS
supplemented with penicillin and transferred into a 100 mm preparation dish containing
MCDB 131. The adventitial tissue was removed manually to avoid contamination of
smooth muscle cells with fibroblasts. The vessel was cut open longitudinally between
the intercostal arteries. The medial layer was cut off in ~ 1-mm2 pieces. The pieces
were transferred to a 50 ml tube containing 1200 U/ml of type IV collagenase in MCDB
131 medium, and incubated at 37ºC with agitation. After 2 hours, the turbid solution was
filtered through an 80-µm cell strainer and centrifuged at 1500 rpm for 15 minutes. The
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supernatant was aspirated off and the cell pellet was resuspended in MCDB 131
supplemented with 50 mg/ml amphotericin B, 50 ng/ml FGF-2, 10 ng/ml EGF, and 0.5
U/ml insulin, 10 % FBS and 100 U/ml penicillin and 100 U/ml streptomycin. Cells were
seeded on tissue culture plates at 5000 cells/cm2 and incubated at 37ºC in 95 % air/5 %
CO2. Porcine aortic smooth muscle cells attached within 24 hours. Using the similar
procedure explained in endothelial cell isolation, the smooth muscle cells were
subcultured and quantified. Smooth muscle cells from passages 1 and 2 were used in
subsequent cultures.

4.4.2.3 Cell Phenotype Evaluation
Smooth muscle cells were seeded in 35 mm dishes at a density of 3000 cells/cm2
and cultured for 48 hours.

Cells were washed with 1X PBS and fixed in 4%

paraformaldehyde in PBS for 10 min.

After washing twice with PBS, cells were

permeabilized with 0.2% Triton X-100 in PBS solution for 90 sec and blocked with 1%
non-fat dry milk in 1X PBS for 30 min. Cells were washed again and incubated with
FITC labeled, monoclonal, anti-smooth muscle α-actin for 3 hours in the dark at room
temperature, and counterstained with 300 µM DAPI for 5 min. After a final wash, cells
were examined under a Nikon inverted epifluorescence microscope.
Endothelial cells were seeded under similar conditions as smooth muscle cells
and cultured up to 48 hours. After washing with 1X PBS, cells were incubated with 200
µL of 1 mg/ml DiI Ac-LDL in phenol red-free DMEM for 3-4 hours. Then, the cells were
counterstained with 300 µL of 300 µM 4´, 6-diamidino-2-phenylindole (DAPI) (nuclear
counter-stain) was added to the medium in culture dishes and further incubated for 5
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minutes. The cells were again rinsed with 1X PBS and examined under the fluorescence
microscope.

4.4.2.4 Preparation of GAG-Chitosan and GAG-Collagen-Chitosan Membranes
Covalently linked collagen-chitosan was prepared as follows. Chitosan (1.5 g) was
dissolved in 95 ml of 0.1 M HCl at room temperature. To this solution was added 0.083
g of Type I collagen in 5 ml of 1 mM HCl. Collagen-chitosan linking was initiated by
addition of 15.9 mg EDC with stirring. After 4 hours, the polymers were precipitated by
adding an excess of 10 M NaOH. The precipitate was washed several times with 1X
PBS and redissolved in 95 ml of 1% acetic acid. Then 0.083 g of Type I collagen in 5 ml
of 1mM HCl was added, to this solution. Unmodified chitosan solution was prepared by
dissolving 1.5 g of chitosan in 1% acetic acid.
Dextran sulfate was carboxymethylated with chloroacetic acid using the method of
Brunswick [78]. Chloroacetic acid (1M) in 3M NaOH solution was used to dissolve
dextran sulfate polymer to a final concentration of 40 mg/ml. The solution was allowed to
react for 70 minutes at room temperature and reaction was then stopped with sodium
phosphate. The pH was adjusted to 7.0 and the carboxymethyl dextran sulfate (CMdextran sulfate) polymer precipitated with isopropanol, centrifuged and the pellet
redissolved in 1X PBS to a final concentration of 40 mg/ml.
Membranes were prepared in 24 well plates using 50 µl of 1.5 wt% chitosan or 1.5
wt% chitosan-5 wt% collagen solution per well. The solution was air dried for 24 hours
and neutralized with 0.2 M sodium hydroxide. Heparin solution (2.5 mg/ml in PBS) or
CM-dextran sulfate solution (40 mg/ml in PBS) was pre-activated by adding 10 fold molar

28
excess of EDC (based on moles of carboxyl) for 15 minutes. Volumes of the activated
solutions were applied to each well to achieve GAG/chitosan mass ratios of 0.08, 0.2,
and 1.0 mg GAG/mg chitosan. The reaction was allowed to proceed overnight with
continuous shaking. The GAG solution was removed and stored for analysis and the
derivatized membranes washed several times with PBS. Coated plates were stored
refrigerated until used for culture.

4.4.2.5 Quantitative Analysis of GAG Immobilization
The amount of GAG (heparin or CM-dextran sulfate) bound on chitosan or
chitosan/collagen surfaces were quantified indirectly by determining the amount of
unbound GAG remaining in the reaction solution.

Safranin-O dye standard was

prepared at a concentration of 0.2 mg/ml in 50 mM sodium acetate buffer (pH 7.4).
Spent GAG reaction solutions were collected from the wells, and 30 µl of this solution
was mixed with 270 µl of Safranin-O in a 96-well plate. The mixture absorbance was
read at 510 nm. Standard calibration curves were prepared for heparin and CM-dextran
sulfate.

The concentration of GAG was determined from the standard curve and

subtracted from the concentration initially applied to each membrane. The difference
was reported as the amount of GAG bound to the membrane.

4.4.2.6 Quantitative Analysis of GAG Immobilization using Toluidine Blue
The presence of GAG on chitosan and chitosan/collagen membranes was
confirmed by staining the membranes with 0.15 mg/ml Toluidine blue in 50 mM sodium
acetate for 10 minutes. The unbound dye was washed away with dH20 for several
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minutes. High quality images of the stained membranes were taken using a Nikon digital
camera using short focus settings.

4.4.2.7 Adsorption of Serum Adhesion Proteins on GAG-Chitosan Membranes

Fibronectin and Vitronectin Adsorption
The protein adsorption on the membranes was evaluated by an immunoassay for
fibronectin and vitronectin. The GAG modified chitosan and chitosan-collagen
membranes were incubated with culture medium containing 10% fetal bovine serum at
4°C overnight. The unbound proteins were then washed with four changes of 1X
phosphate buffer solution (PBS) over 2 hours. The unspecific binding sites on the
membranes were blocked using 3% non-fat dry milk in one X PBS. Then the surfaces
were treated with rabbit anti-bovine fibronectin (dilution 1:5000, 150µl per well) for 2
hours at room temperature. Then the surfaces were treated with Anti-Rabbit IgG –
alkaline phosphatase conjugate (dilution 1:15000, 150µl per well) for two hours at room
temperature. Subsequently, secondary antibody incubation, the surfaces were washed
with PBS three times 10-15 minutes each at each step. Finally, the surfaces were
incubated with p-Nitrophenyl Phosphate (pNPP) solution in water (0.6 ml/well) for
approximately 30 minutes at room temperature in dark and the color progress was
constantly watched. After that the 150 µl of stop solution (3N NaOH) was added to each
of the wells. At the final point, the absorbance values of the solutions were taken at 405
nm.
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4.4.2.8 Cell Culture and Measurement of Adhesion, Spreading and Growth Kinetics
on Polysaccharide Surfaces
Porcine SMC and EC were seeded at a density of 5000 cells/cm2 on heparin and
CM-dextran sulfate immobilized onto membranes of chitosan or collagen-chitosan. The
SMC were also cultured on chitosan and collagen surfaces with heparin, heparan
sulfate, chondroitin sulfate A and carboxymethyl dextran at a GAG/chitosan ratio of 1
mg/mg. Cultures were maintained at 37ºC in a humidified 5% CO2 atmosphere. Plastic,
pure chitosan and collagen-chitosan membranes were used as control culture surfaces.
At the end of second day of culture, at least 15 images were captured using phase
contrast microscope with the 10X objective after removing the unattached cells. These
images were used to determine the surface area and shape factor of the cells attached.
The attached cells have a shape factor value, smaller than one, where shape factor
corresponds to a perfectly round cell.
Shape Factor = [4π (Area)]/ (Perimeter) 2 = 1

The area and shape factor were measured using the computer software Sigma Scan Pro
5 to determine the degree of cell spreading on the studied surfaces.
Cell proliferation was quantified using the Alamar Blue assay. For this assay,
culture membranes were prepared in 96-well plates by scaling down the techniques
presented above.

Cells were seeded at a density of 5000 cells/cm2.

Plastic, pure

chitosan-collagen and chitosan membranes were used as controls for these studies.
After a 48 hours and 96 hours of culture, the culture medium was replaced with phenol
red-free DMEM medium containing 10% Alamar Blue, 10% FBS and antibiotics. After 6
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hours of exposure, the culture medium absorbance was read at 570 nm and 600 nm.
The percent reduction of Alamar Blue was calculated by the following equation:



F (dayx) − F (control )

% Re duction = 
 F (100%reduced ) − F (control ) 
Where
F (day x) =Flourometric reading of cell culture on day X;
F (control) = Flourometric reading of Alamar Blue/cell culture medium and
F (100% reduced) = Reading of autoclaved Alamar Blue/cell culture medium.
At the exponential growth phase, the growth kinetics are given by the equation using
reduction values

ln(

A
) = µ A (t − t0 )
A0

Where,
A = the reduction rate measured by Alamar Blue,
t = time in days
µA =the specific growth rate for both SMC and EC in hr-1 were calculated.

4.4.2.9 Observation of Cytoskeleton Organization
SMC were seeded on GAG-modified membranes in 24 well plates at a density of
3000 cells/cm2. On day 2, the cells were washed with PBS and fixed in 4%
paraformaldehyde in PBS for 10 minutes, permeabilized with 0.1% Triton X-100 for 1
minute, and blocked with 5% non-fat dry milk for 30 minutes. In between each step, the
cell layer was washed away with PBS. Cells were incubated with rhodamine-phalloidin
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in DMEM, which was removed with three changes of PBS with 0.05% Tween-20 (wash
buffer) over 30 minutes. Nuclei were counterstained with DAPI for 5 minutes and cells
were imaged using an inverted epifluorescence microscope.

4.5 RESULTS
4.5.1 Cell Isolation and Characterization
After culturing freshly isolated SMCs and ECs for 48-72 hours, cell phenotype and
culture purity were evaluated using immunofluorescence. Figure 4.5 shows that SMC
expressed high levels of smooth muscle α-actin (Figure 4.5 B), while cellular uptake of
DiI-acetylated-LDL confirmed endothelial identity (Figure 4.5D). Attempts to stain EC
with anti-smooth muscle α-actin and SMC with DiI-AcLDL confirmed negligible cross
contamination of SMC and EC cells.
experiments at passages 1, 2 and 3.

SMC and EC were used for subsequent
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(a)

(b)

(c)

(d)

Figure 4.5 Morphologic changes of isolated cells (a) Phase contrast image of smooth muscle cells
(10X).(b) Fluorescent image of smooth muscle cells with cells stained with anti-α- smooth muscle
actin for actin fibers (green).(c) Phase contrast image of endothelial cells (10X).(d) Fluorescent
image of endothelial cells where cells uptake of DIL-acetylated low density lipoprotein (red).
Nuclei stained with DAPI (blue). Scale bar: 125 µm
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4.5.2 Qualitative Analysis of GAG Immobilization using Toluidine Blue
The amount of GAGs immobilized on the membranes prepared as presented
previously were assessed qualitatively by Toluidine blue staining. Toluidine Blue is a
cationic dye that binds to the negatively charged sulfate and /or carboxyl groups in the
GAGs. The staining of the membranes with the Toluidine Blue confirms the presence of
immobilized GAGs. Unmodified chitosan does not possess any negatively charged
groups, and thus the unmodified chitosan membranes were not projected to be stained
with Toluidine blue.
Images of Toluidine Blue stained membranes prepared with the GAGs using a
CCD camera were captured. The increasing level of Toluidine blue staining on the
membranes as a function of increasing GAG density was visible in the images. GAG
stained with Toluidine blue that has a ring pattern of staining was observed depending
on the density of GAG used; hence, the non-uniform staining of the membranes
indicated that GAG binding on the membranes was not the same. The non-uniformity
can be related to the inconsistent membrane structure caused by the formation of
uneven stresses on the membrane surface during the air-drying step in the membrane
preparation.
The degree of saturation appeared to reach a maximum level at GAG/chitosan
ratio of 0.2 mg/mg for all the GAGs. At saturation, the level of staining on the modified
membranes was the highest on those prepared with heparin and heparan sulfate
followed by the CM-dextran sulfate and chondroitin sulfate A. The saturation pattern
observed may be due to the bound GAG or the saturation of the GAG within the
Toluidine Blue stain. For clarification, it is necessary to analyze the membranes amount
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of bound GAG using a quantitative method. The degree of saturation present within the
toluidine staining appears correlated with the degree of sulfation in the GAG. It is known
that heparin and heparan have more sulfate groups than the other GAGs. There is no
distinct difference between Toluidine Blue staining for the chitosan and chitosan/collagen
surfaces.

(a)
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(b)
Figure 4.6 Toluidine blue staining of glycosaminoglycans linked chitosan membranes
(a) Chitosan; (b) Chitosan/collagen

4.5.3 Quantitative Analysis of GAG Immobilization using Safranin-O
The covalent immobilization resulted in the immobilization profile as a function of
the GAG applied shown in Figure 4.8 a, b. Covalently GAG immobilization onto chitosan
and chitosan-collagen membranes via EDC was characterized by quantifying the amount
of immobilized GAG.

Amounts of heparin and CM-dextran sulfate immobilized on

chitosan and chitosan-collagen membranes were calculated and expressed as
GAG/chitosan or GAG/chitosan-collagen mass ratio. The amount of bound GAG was
calculated using the standard equations presented in Figure 4.7.The quantitative results
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showed that level of GAG applied to the membranes increased ranging from 0.01 mg –
0.19 mg at 0.08 mg/mg ratio and 0.06 mg-0.33 mg at 1mg/mg of the amount initially
applied. On the other hand, when collagen is present the level of CM-dextran sulfate
immobilized increased. The same behavior is present for heparin with the exception that
as the GAG reaches 0.2 mg/mg, the amount of GAG immobilized decreases. The actual
amount of GAG immobilized on the membranes remained relatively constant between
collagen and non-collagen surfaces.

Figure 4.7 GAG standards for Heparin and CM-Dextran Sulfate
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Figure 4.8 Amount of immobilized GAG/chitosan on (a) chitosan; (b) chitosan-collagen surface.
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4.5.4 Adsorption of Serum Adhesion Proteins on GAG-Chitosan Membranes
Fibronectin and vitronectin are two dominant serum glycoproteins that are
important for attachment and spreading of cultured cells [79]. Fibronectin, has been
localized in a variety of basement membranes and has specific sites for matrix
components including collagen and glycosaminoglycans [46]. For anchorage dependent
cells like SMC and EC, adhesion to the culture surfaces is essential because adhesion
involves immobilized ligands, which lead to proliferation, differentiation and cell death.
Cell attachment includes the interaction between the cell surface receptors and the
ligands present on the culture surface. In vitro, cell adhesion occurs because of the
affinity binding of integrins (cell surface receptors) to serum proteins (fibronectin,
vitronectin).
The absorption of serum adhesion proteins, vitronectin and fibronectin on GAG
modified chitosan membranes was determined. The membranes were incubated
overnight with medium containing 10 % FBS and reach levels of adsorption of fibronectin
and vitronectin were determined using an ELISA based immunoassay. Figure 4.9 shows
the protein absorption profiles on the chitosan membranes. However, to understand the
influence that absorbed proteins have on SMC and EC behavior, absorbances of
fibronectin and vitronectin from medium containing 10 % fetal bovine serum on GAGlinked chitosan membranes were evaluated.
The amount of fibronectin adsorbed on the GAG-chitosan membranes increased
with a high level of GAG immobilized on the surface for all GAG except for heparan
sulfate and chondroitin sulfate A (Figure 4.9a). CM-dextran sulfate derivatized
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membranes showed the highest level of fibronectin amount on the lowest GAG /chitosan
ratio, but heparin derivatized chitosan membranes showed the highest level of absorbed
proteins for the GAG density of 0.2 and 1 mg/mg. Alternatively, vitronectin adsorption
levels on GAG-linked chitosan membranes were also determined (Figure 4.9b). The
highest level of vitronectin attachment is on plastic control but from the immobilized GAG
surfaces, the highest level of vitronectin absorption was on CM-dextran sulfate
immobilized surfaces over the GAG density range studied. Then, heparin-derivatized
chitosan membranes followed it even though the differences between the two GAGS
were found to be statistically insignificant at high-density ratios. The lowest vitronectin
levels were measured for heparan sulfate and chondroitin sulfate A. Overall, the highest
level of vitronectin increased at the GAG density of 0.2 mg/mg.
0.5
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Figure 4.9 Chitosan surface protein absorption: (a) fibronectin; (b) vitronectin. Data expressed as
mean + standard deviation, ⃰ P < 0.01.

In order to understand the influence of absorbed proteins on chitosan and
chitosan- collagen surfaces, the absorption of fibronectin and vitronectin from medium
containing 10 % fetal bovine serum was evaluated qualitatively. The amounts of
fibronectin adsorbed on chitosan surfaces are higher than on chitosan-collagen surfaces
in the presence of CM-dextran sulfate for GAG density of 0.08 mg/mg. The amount of
fibronectin, absorbed on chitosan/collagen surfaces displayed similar levels of adsorbed
fibronectin among GAG-membranes over the range of GAG density studied.

Even

though, there are slightly higher amounts of fibronectin on heparin and CM-dextran
derivatized surfaces at GAG densities below 0.2 mg/mg, there is no statistical difference
between them, hence the fibronectin is absorbed relatively at the same level. On the
other hand, vitronectin absorption is higher for GAG density under 0.2 mg/mg for
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heparin-derivatized surfaces. Heparin and CM-dextran sulfate immobilized surfaces at
GAG density of 1 mg/mg displayed similar levels of vitronectin. The amount of vitronectin
absorbed on chitosan/collagen surfaces exhibit similar levels of adsorbed vitronectin
among GAG-membranes over the range of GAG density studied.

The presence of

collagen had no effect on the amount of fibronectin and vitronectin level added over the
GAG range studied.
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Figure 4.10 Fibronectin attachment on (a) chitosan; (b) chitosan-collagen. Statistics calculated
using one-way ANOVA. No statistical difference between surfaces.
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Figure 4.11 Vitronectin attachment on (a) chitosan; (b) chitosan/collagen. Statistics calculated
using one-way ANOVA. No statistical difference between surfaces.

4.5.5 Morphology of SMC and EC on GAG-Modified Surfaces
Culture morphology and cell spreading of SMC and EC were evaluated using phase
contrast microscopy after cells were cultured for 4 days (Figure 4.12, 4.13). Phase
contrast images established that the GAG type present in the membranes influenced
SMC and EC morphology. While comparing all of the GAGs, we can distinguish that
higher growth occurs on heparin-immobilized surfaces when collagen is present, and on
chondroitin sulfate A and CM-dextran sulfate immobilized surfaces when collagen is
absent.
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Chitosan

Chitosan –Collagen

Figure 4.12 Smooth muscle cells morphology on different membranes.
GAG/chitosan ratio of 1 mg/mg (4X).

Among controls, higher growth of SMC was obtained on plastic in comparison to
chitosan-collagen. SMC had low proliferation and retained a circular shape on chitosan
surfaces. On heparin-collagen/chitosan surfaces, improved SMC growth was observed
at higher levels of immobilized heparin for all GAG-material ratios used. On the other
hand, on heparin-chitosan surface, SMC proliferation was inhibited for all GAG-material
ratios. Thus, it can be noted that inclusion of collagen effectively reversed the antiproliferative effect of heparin on SMC. Heparinized chitosan surfaces have an increased
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number of cells that are rounded similar to pure chitosan surface. Similarly, the addition
of collagen to the heparinized surfaces had a positive effect on SMC spreading, as
demonstrated by the increase in the projected cell area and decrease in shape factor
values shown in Figures 4.14A and 4.15 A , respectively. On the CM-dextran sulfate
surfaces, SMC cells have a relatively poorer growth on the collagen-chitosan surface in
comparison to the chitosan surface. Inclusion of collagen for these surfaces diminishes
the growth of SMC on CM-dextran sulfate surfaces, but the growth is still higher than on
heparinzed surfaces.
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Figure 4.13 (a) Smooth muscle cells morphology on different membranes (4X).(A) chitosan (B)
chitosan /collagen. (C) plastic. (D-F) heparin collagen-chitosan surface at 1, 0.2 and 0.08 mg/mg,
respectively. (G-I) heparin-chitosan surface at 1, 0.2 and 0.08 mg/mg respectively. (J-L) CM-dextran
surface at 1, 0.2 and 0.08 mg/mg, respectively. (M-O) CM-dextran surface at 1, 0.2 and 0.08 mg/mg,
respectively. (b) Endothelial morphology on different membranes (4X). A. chitosan. B. collagenchitosan. (C) Plastic. (D- F) heparin collagen-chitosan surface at 1, 0.2 and 0.08 mg/mg,
respectively. (G-I) heparin-chitosan surface at 1, 0.2 and 0.08 mg/mg, respectively. (J-L) CM-dextran
surface at 1, 0.2 and 0.08mg/mg, respectively. (M-O) CM-dextran surface at 1, 0.2 and 0.08 mg/mg,
respectively. Scale bar: 100 µm

EC demonstrated a high proliferation and similar morphology on all control
surfaces as shown in Figure 4.13b.

On heparin-collagen-chitosan surfaces EC

proliferation was higher than on heparin-chitosan surfaces for all GAG-chitosan ratios.
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However, EC proliferation on CM-dextran sulfate showed no differences in proliferation
between the collagen-chitosan and chitosan membranes. EC appeared to reach 80% to
90% confluence on the CM-dextran sulfate-collagen-chitosan surface after 96 hours.
In order to understand the effects of GAG type and density on the characteristics
of SMC and EC culture, the extent of adhesion and spreading was quantified. EC and
SMC were cultured on GAG modified membranes for 48 hours. After the 48 hours,
microscopic images were captured. The images were used to determine the shape factor
and spreading area for SMC and EC cultured on various GAG modified membranes.
Spreading data (Figure 4.14; Figure 4.15) for collagen-chitosan/ surface showed no
difference in EC morphology between the heparin-modified and CM-dextran sulfatemodified versions. These results showed that the presence of collagen in these GAGchitosan biomaterials had a significant beneficial effect on SMC but not EC attachment,
spreading and proliferation.
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Figure 4.14 Surface area (a) smooth muscle cells on control, collagen-chitosan and chitosan
surface; (b) endothelial cells control, chitosan – collagen and chitosan surface. Data expressed as
mean + standard deviation. Statistics calculated using one-way ANOVA. ⃰ P <0.05 for SMC
surfaces. No statistical difference for surfaces seeded with endothelial cells (P>0.05).
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Figure 4.15 Shape factor (a) smooth muscle cells control, collagen-chitosan and chitosan surface;.
(b) endothelial cells control, collagen-chitosan and chitosan surface. Data expressed as mean +
standard deviation. Statistics calculated using one-way ANOVA. ⃰ P <0.05. No statistical
difference for surfaces seeded with endothelial cells (P>0.05).

4.5.6 Growth Kinetics of SMC and EC on GAG-Modified Surfaces
The degree of cell spreading is frequently linked with the degree of growth
response; as a result, the proliferation rates on the GAG-modified surfaces were
evaluated using the percent reduction of Alamar Blue. The proliferation rate was
evaluated for SMC cells grown on GAG-modified chitosan membranes. The values are
then used to calculate a specific growth rate.
Figure 4.16 shows the effects of GAG type and density on the specific growth rate
of SMC and EC. The specific growth rate displayed in Figure 4.16 a shows that growth
rate for pure chitosan decreases in comparison to plastic and chitosan-collagen. Smooth
muscle cell growth rate is higher on covalently derivatized CM-dextran surfaces when
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GAG-chitosan ratio was around 1mg/mg GAG to chitosan ratio in comparison to heparin
surfaces when collagen is absent from the material.
In the presence of collagen, the smooth muscle cell growth rate is slightly lower
for the CM-dextran sulfate than heparinzied surfaces. Overall, the growth rate for smooth
muscle cells was the highest on CM- dextran sulfate surface when GAG to chitosan ratio
was 1mg/mg. On the other hand, the specific growth rate for heparinized chitosan
surfaces with collagen was constant around 0.037 hr-1 which correlates with the phase
contrast images as shown in Figure 4.13a.
For endothelial cells, the specific growth rate is higher at GAG-chitosan growth
ratio 0.08 mg/ mg for CM-dextran sulfate and heparinized surfaces in the presence of
collagen. When comparing the growth rate between the CM-dextran sulfate and heparin
surfaces, the growth rate decreases. At peak value, the growth rate for endothelial cells
was around 0.05 hr-1. There is a slight decrease in growth rate for heparinized surfaces
in comparison with CM-dextran sulfate surfaces in the absence of collagen. Figure 4.16b
shows that when GAG-chitosan ratio was increased for CM-dextran sulfate surfaces, the
specific growth rate decreases in the presence of collagen but remains relatively
constant when collagen is absent. On the other hand, when the GAG-ratio was
increased for heparinized surfaces, the specific growth rate remains relatively constant
for all ratios and decreases between GAGs.
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Figure 4.16 Cell proliferation using Alamar Blue on: (a) smooth muscle cell (b) endothelial cell.
Statistical difference calculated using ANOVA between chitosan and collagen surfaces and
between carboxymethylated dextran sulfate and heparin. Data values are the average + growth rate
values, ⃰ P < 0.05.

4.5.7 Cytoskeleton Organization
SM α-actin is the most abundant cytoskeleton protein involved in cell contraction
[68]. The extent of cell spreading and cytoskeleton organization in smooth muscle cells
were analyzed by fluorescent staining of actin fibers. SMC were cultured on GAG
immobilized membranes in the presence of collagen and absence of it. The cells were
fixed on after 48 hours for staining. The organization of cell fibers shows the extent of
cell spreading on surfaces. Figure 4.17 shows the fluorescent images of stained cells.
Cell grown on chitosan/collagen surfaces have a more visible cytoskeleton organization
in comparison to those on chitosan surfaces. The cells were aligned in a more organized
fashion when collagen is present, even though the actin fibers structure could not be
clearly seen.

55

(B)

(A)

Chitosan

(C)

Heparin-Chitosan Collagen
(1mg/1mg)

(E)

CM-Dextran Sulfate-Chitosan
Collagen (1mg/1mg)

Chitosan-Collagen

(D)

Heparin-Chitosan (1mg/1mg)

(F)

CM-Dextran Sulfate Chitosan
(1mg/1mg)

Figure 4.17 Cytoskeleton organization staining with Rhodamine-Pholloidin.
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4.6 DISCUSSION
Chitosan has shown potential as a structural material due to the presence of cationic
group in the chitosan involved in electrostatic interactions with anionic cell membranes
leading to cell growth, attachment and proliferation [80]. In addition, the analysis and
quantitation of cell-material interactions and the molecular, structural and biological
structure-property relationships derived from this data will provide a more detailed broad
understanding, which helps in improving the strength, uniformity and cellular organization
of the vessels. The ramifications of this increased understanding are difficult to predict,
but improvements in development of a tissue-engineered blood vessel can be expected
to benefit from this work
In part of the project, we evaluated morphological and growth responses of
vascular smooth muscle and endothelial cells cultured on immobilized chitosan-GAG
surfaces.

Prior to determining which biomolecules are beneficial to growth and

proliferation of SMC and EC, we tested several glycosaminoglycans such as heparin,
heparan sulfate chondroitin sulfate A, dermatan sulfate and carboxymethylated dextran
sulfate. These GAGs were immobilized on two test surfaces: chitosan and chitosancollagen (cross-linked/blended). The collagen was crosslinked using EDC, which
resulted in formation of amide crosslinks between carboxylic groups and free primary
amino groups from amino residues of collagen [81] which lead to a stabilization of
collagen from denaturation [82].
The immobilization of heparin and CM-dextran sulfate on chitosan films and
collagen-chitosan films and their effects on the morphology and proliferation of aortic
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smooth muscle cells and endothelial cells show potential to determine a beneficial
biomaterial.
Our results indicated, CM–dextran sulfate-chitosan material can enhance
attachment and growth of smooth muscle cells and endothelial cells hence CM-dextran
sulfate has a growth binding activity similar to heparin [85, 86] which can modulate the
biosynthesis of collagen and glycoproteins by SMC [83].

Heparin and collagen I

interactions are site dependent not sequence independent. The triple helical structure of
type I collagen is needed for the high binding to heparin [87], which had an effect on cell
proliferation on heparin-chitosan and heparin-collagen-chitosan.
Previous studies indicate that heparin has an antiproliferative effect on SMC due
to a large number of O-sulfo groups [84]. In our study, heparin covalently cross-linked
with chitosan showed the existence of the antiproliferative effect, but when the surface
contained collagen, heparin had a proliferative effect on SMC. For CM-DXS, covalently
cross-linked with chitosan-collagen surface, CM-DXS competes with collagen amino
groups for the attachment sites on chitosan thus explaining the decrease proliferation
behavior of SMC. Earlier research show that highly anionic carboxylic dextrans are not
capable of inhibiting the SMC growth [88].The inhibitory effect exhibited by smooth
muscle cells was not present in endothelial cells seeded on covalent linked heparinchitosan and heparin chitosan surfaces. The effects of heparin are cell specific,
glycosaminoglycan specific and vary in biological responses [90-92].
We demonstrated that presence of collagen with immobilized heparin stimulated
both SMC and EC attachment and proliferation. The highest amount of bound heparin
occurring at the intermediate ratio for chitosan-collagen surface implying that there was a
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correlation with the bound heparin on the surface and cell attachment indicating that cell
attachment and proliferation might depend on the chemical and physical properties of the
surfaces seeded [89].
On plastic and chitosan-collagen, smooth muscle cell spreading and proliferation
was increased in comparison to chitosan surface. On the other hand, endothelial cells
spread, proliferated and attached well on all control surfaces. In summary, covalently
linked heparin to collagen-chitosan surface boost endothelial cell and smooth muscle cell
growth, spreading and attachment.
ECM proteins such as fibronectin and vitronectin mediate adhesion, migration and
proliferation. Fibronectin and vitronectin were selected because they are the most
abundant adhesion proteins found in serum and found in the extracellular matrix
immobilized through their GAG-binding sites. They have known to mediate cellular
functions such as adhesion, migration, differentiation by their ability to bind integrins [92].
Absorbed fibronectin has been previously shown to enhance proliferation and
attachment of endothelial cells [93]. Our results indicate that the amount of fibronectin
and vitronectin absorbed depends on the on the type and density of GAG present on the
surfaces. According to our studies, heparin and CM-dextran sulfate have highest level of
absorbed protein binding (fibronectin and vitronectin), which enhances cell attachment
as a result. The extensive growth response to CM-dextran sulfate scaffolds suggests that
GAG desorption from such scaffolds can help stimulate tissue regeneration.
Aortic smooth muscle cells contained a cytoskeleton comprised of actin filaments
and intermediate filaments with their complements of associated proteins [94, 95]. In the
last part of the chapter, we looked at cytoskeleton organization of SMC grown on the
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surfaces mentioned above. We observed that actin fibers are present but there is no
apparent

orientation.

In

summary,

this

study

indicated

that

heparin

and

carboxymethylated dextran sulfate chitosan-collagen films supported attachment and
proliferation SMC and EC.

4.7 RECOMMENDATIONS
Even though the GAG density was analyzed both qualitatively and quantitatively,
the surfaces should be further examined for structural characterization and roughness.
The changes in the structure can be analyzed using differential scanning calorimetry
which will yield the membrane crystalline structure. In addition to the differential scanning
calorimetry, X-ray photoelectron spectroscopy can be used to determine the atomic
composition of the surfaces.
The mechanism of the effects of immobilized heparin on collagen surfaces in
culture should be further investigated, to see what effect the crosslinking has on
absorption of adhesion proteins.
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Chapter 5
SCAFFOLD FABRICATION AND SEEDING

5.1 INTRODUCTION
Vascular grafts are used to replace, maintain function of damaged, occluded and
diseased blood vessels in large diameters. These grafts are attained with autogeneous
and artificial grafts. Vascular prosthesis are manufactured from synthetic, biological and
natural derived materials [96]. These materials encounter proteins, cells, tissues, organs
and organ systems.
The performance of vascular prosthesis is measure by the time they are patent.
The autogeneous grafts continue to be used for bypass procedure. The amounts of
artificial prostheses are inadequate. Synthetic prostheses are usually made of PTFE or
Dacron. Biological prostheses can be either xenografts or allografts. Allografts are blood
vessels from cadaveric blood vessel grafts, removed varicose veins or human umbilical
vein grafts. Xenografts are usually animal in origin. The techniques used to create these
vascular scaffolds include emulsion freeze drying, phase separation and fiber meshes.
A critical requirement for tissue growth in vivo or for providing a template for
directed tissue assembly is the ability to fabricate porous microstructures from these
materials. The porous vascular scaffold serves as a matrix for initial cell attachment,
provides a suitable substrate for cell attachment, migration, proliferation and
differentiation, and to support and guide the in-growth of cells [45, 97, 98]. The
requirements that have been recognized as essential to tissue engineering scaffolds
include biocompatibility, interconnected pores, controlled biodegradability and adequate
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mechanical properties to implantation [99]. The three dimensional

vascular scaffold

chemistry may mimic extracellular matrix components, growth factors, cell surface
receptors [45] and pore size. The pore size influences the effectiveness of cell seeding,
attachment, proliferation, nutrient and oxygen transport within the 3-D structure.
Natural biomaterials for scaffold fabrication include purified ECM proteins, ECM
derivatives and small intestinal submucosa acelular matrix as well as materials derived
from plants and crustaceans. Natural biomaterials mimic similar functional and structural
properties to the native extracellular environment [100]. They are both biodegradable
and biocompatible. Hence, we choose to use chitosan and collagen as the main
structural components of our vascular scaffolds. These scaffolds aim to substitute
damaged tissue, as well as support, reinforce and organize regenerated tissue and are
extremely promising for tissue engineering applications. The average pore diameter
must be large enough for cells to migrate and small enough to retain a critical total
surface area for cell binding to increase the benefit of vascular seeding. The optimal
scaffold pore size that allows maximal entry of cells as well as cell adhesion varies with
different cell type. High porosity, enables maximal conversion of cells and tissue invasion
necessary for tissue construction [101] .

5.2 SPECIFIC AIMS
The working hypothesis of this part of the project was that homogeneous porosity,
cell distribution and entrapment is an essential feature of a successful vascular graft. In
order to test this hypothesis, the specific aim 2 was established. The specific aim 2 was
to determine how incorporation of collagen (bulk or gel) and GAG into chitosan scaffold
would facilitate cellular entrapment, proliferation and organization. In order to test this

62
hypothesis we evaluated the effects of varying the acetic acid concentration on the pore
structure of chitosan and chitosan/collagen scaffolds. Secondly, SMC were seeded on
these scaffolds using a range of seeding techniques. The efficiency of the seeding
technique was estimated by determining the amount of cells trapped, in addition to the
distribution and viability of the cells within the scaffolds.

5.3 BACKGROUND
5.3.1 Background of Vascular Graft Research
A variety of scaffold materials has the potential of fabricating vascular scaffolds with
appropriate mechanical strength, biological and physico-chemical characteristics for the
development of vascular tissues. These are divided into three categories:
I.

Synthetic Biomaterials –Polytetrafloroethylene (PTFE) and Dacron.

II.

Biodegradable Biomaterials– Polyglycolic acid (PGA), Polylactic acid (PLA),
Polygalactin (PGA-PLA copolymer), Polyhydroxyalkanoate (PHOH), Poly-4hydroxybutyrate (P4HB).

III.

Natural Biomaterials - Autologous Human Tissue, Decellularized Matrix, Small
Intestine Submucosa, Fibrin Gel, Collagen and Chitosan.

Scaffolds are essential in achieving tissue reconstruction and provide structural
integrity until the cells fabricate their own extracellular matrix. It is crucial for scaffolds to
have a high porosity, adequate pore size and have biodegradable properties. The
biodegradability of the scaffold should be at the same rate as the tissue formation.
With the aim of generating porous scaffolds having the necessary pore orientation
and pore size, numerous factors come into effect [45]. The factors include:
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I.

Dry ice methanol bath freezing method: Using dry ice with an organic solvent can
provide temperatures down to -70°C for longer period .

II.

Concentration of the solution: It has an inverse relationship with porosity because
as the concentration is increased, the total amount of ice crystals reduces hence
lowering final porosity.

III.

Freezing rate: It has an inverse effect on pore size because as the freezing rate
increases the pore size decreases. This occurs because the mass transfer instead
of heat transfer at lower temperatures dominates the system.

IV.

Direction of the heat transfer: It has a large effect on pore orientation, especially in
a tubular mold where the solution was frozen in the radial direction with the base
and top insulated.

Seeding cells into a scaffold at high densities allows cell-to-cell interaction and
development of the tissue. The uniform distribution of cells within the scaffold can create
a basis for homogeneous tissue generation [102].
The architectural properties of the scaffold dictate the transport that occurs within
as a function of diffusion. The size, geometry, orientation, interconnectivity, branching
and surface chemistry of the pores and channels directly affect the nature of nutrient
diffusion and tissue growth [103-105]. Because of the architecture of 3-D scaffolds,
dispersing a high density of cells with uniform distribution, efficiency and viability is a
challenging task. Besides seeding a greater number of cells, it is vital to achieve efficient
dispersion and migration of cells within the scaffold. Prior research demonstrated that the
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uniformity of generated tissue was correlated with the homogeneity of cell distribution
after scaffold seeding [106, 107].

5.3.1.1 Synthetic Biomaterials in Current Vascular Grafts
The use of synthetic materials is the oldest approach for vascular graft
development.

In 1952, Voorhees found that plastic tubes can be accepted into the

organism if they had a porous wall and were biocompatible. [108]. At the time, blood
vessels were considered just simple delivery systems. As the years passed, researchers
have distinguished the biological aspects of the blood vessels. A vascular graft was
proposed to mimic the natural blood vessels properties and functionality. Enhancement
of synthetic materials evolved as a need to enhance graft patency. Research illustrated
that over short time periods these materials were adequate, but the problems occurred
when extensive periods passed.
The most frequent grafts used for vascular graft replacement include woven
Dacron (polyethylene tetraphalate) and ePTFE (expanded polyterafluoroethylene) [109114]. The enhanced hydrophobic characteristics of these materials and increased
crystallinity made them less susceptible to degradation.
DeBakey, first reported the use of Dacron as replacement for vascular prosthesis
[115]. Dacron grafts can be fabricated via knitted or woven forms of fibers, which allow
control of porosity and strength of the material. The woven form of this graft has low
porosity in comparison with the knitted form, which has high porosity and enhanced
dispensability.Surgeons

favor

the

woven

material

because

of

the

following

characteristics: high bursting strengths, low permeability and minimal tendency to deform
under stress [110, 116]. Limited ability to bend these grafts led to use of rings and coils
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on the external surface which in turn permits more flexibility and avoids kinking [117].
The frequent complications associated with these grafts include graft occlusion, graft
infection, distal embolisation and erosion in to the adjacent structures.
ePTFE is a synthetic polymer of carbon and fluorine produced by mechanical
stretching. It is the most accepted non-degradable synthetic polymer and used for
medium to large diameter vascular grafts [118, 119]. The PTFE molecule is biostable
and the graft does not undergo biological deterioration within the body. There is no wear
and tear because the surface of the graft is electronegative which minimizes the reaction
with the blood components. The graft consists of circumferentially aligned, thin and
irregular-shaped solid membranes and a dense meshwork of fine fibrils stretching
between the solid membranes [110, 116] and creates a mesh-like structure with large
flexibility and enhanced mechanical properties. This material is porous which allows the
body’s tissue to grow into it.
ePTFEs are preferred over Dacron due to their kink resistant behavior and the
enhanced patency within the first five years [120]. Long-term patency is still an issue.
However, when implanted it exhibits a five-year patency rate of 91-95 % [7].

The

inherent thrombogenicity of this graft in conjunction with neointimal hyperplasia are the
primary factors for failure.
Polyurethanes (PU), a synthetic biomaterial also been used as a vascular material
for developing alternative graft prosthesis [110, 116, 121-125] over Dacron and ePTFE
due of its elasticity and ease of handling. PUs are copolymers derived from a hard
domain of diisocyanate for strength, a chain extender and a soft domain of a polyol for
flexibility [7]. The control of the three components leads to a material with desired
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mechanical properties. PUs are hydrolytically unstable, prone to oxidative degradation
and exhibit elongation over time with higher incidence of the formation of pseudointima
and formation of carcinogenic products like 2-4-toluene-diamine [126]. The intrinsic inert
property of PU is not positive for endothelial cell growth [127]. Numerous PU vascular
grafts such as Corvita , Thoratec and PulseTec have been designed to be used as
vascular prosthesis in both USA and UK [128]. Carboxylated PU treatment of the graft
can create a surface with a reactive carboxylic acid group. In literature, tissue reactions
to PU are discrepant since factors such as porosity, graft fabrication and surface
modification can influence the results.
PUs were more compliant then ePTFE, resistant to degradation and it is
mechanical and flow parameters are better matched to those of the native vasculature.
On the other hand, the material is hydrolytically unstable, prone to oxidative degradation
and inter-connectivity between pores is largely absent. The intrinsic inert property of PU
is unfavorable for endothelial cell growth [128]. This material has been modified for better
incorporate bioactive components (gelatin, collagen or chitosan) on the scaffold surface.
The modifications includes

incorporation of diazeniumdiolate-modified nitric oxide-

producing peptide [119] and aminolyzed with 1,6-hexanediamide to induce amino groups
on its surface [128].
Synthetic materials are prone to inflammatory cell migration, which directs to cell
infiltration and to protein adsorption, which leads to platelet absorption. These materials
provide adequate mechanical strength.
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5.3.2.2 Biodegradable materials in Current Vascular Grafts
As described, synthetic materials compose most of the present vascular
prosthesis on the market. Given that these materials cannot regenerate, repair or
remodel and cause recurrent infections, synthetic degradable polymers have been
utilized. These materials possess the advantage of leaving behind no prosthetic
materials to elicit foreign-body reactions [129]. Biodegradable materials undergo
fragmentation but their degradation products are much smaller and may not remain
present at the implantation site. A critical criterion for these biodegradable grafts is that
they must regenerate a tissue complex of sufficient strength to minimize an aneurismal
dilatation for clinical use.

The two most investigated biodegradable polymers are

polyglycolic acid (PGA),polylactic acid (PLA) and polycarpolactone (PCL).
PGA is inelastic polyester with high crystallinity and used broadly for fabricating
tissue engineered vascular graft constructs [7, 130] . The main limitation with polyglycolic
acid is considerable weakening of the scaffold during in-vitro degradation due to
hydrolytic chemical scission. In addition, degradation leads to creation of an acidic
environment creating a local inflammatory response leading to early failure of constructs
[131, 132].
PLA polymer contains an extra methyl group as compared to PGA as a result; it is
more hydrophobic in nature. This results in slower hydrolysis rates and long resorption
times. The inflammatory response is somewhat less as compared to PGA [130, 132,
133].
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In vivo PGA and PLA mesh structures by themselves have low mechanical
strength, but when placed in vivo they can absorb proteins and increase cellular
migration. The copolymer of these materials is marketed under the trade name Vicryl
(polyglactin 910). The first fully biodegradable graft was investigated in 1979 and it was
made from Vicryl sheets [134]. The PGA grafts made by Bowald, illustrated that
migration of myofibroblasts from the surrounding tissues while the graft lacks control
over PGA degradation and has a confluent monolayer over the PGA degradation and
tissue formation.
The PGA polymer does not possess cell-anchoring sites, hence surface
modifications are needed to facilitate cell growth, cell distribution or both. The simplest
modification to PGA is the treatment with sodium hydroxide, which results in
transforming ester groups to hydroxyl and carboxylic groups. Cell attachment has been
shown to double using this method [135]. Another typical surface modification includes
incorporation of RGD sequence to the polymer surface to enhance cell adhesion [136].
Additional adhesion peptides like RGD and REDV have been recognized for use as cell
recognition sites.
Nerem & Seliktar and Niklason et al used synthetic PGA meshes as scaffolds.
Their constructs exhibit burst pressures higher than 2000mm Hg and desirable cell
adhesion

[137, 138].

Modification of PGA-PLA has been shown to modulate cell

adhesion, cell phenotype, promotes elastin increase, collagen production [139-141].
PGA-PLA in the amorphous form is a high porosity, open pore system that degrades in
2-6 months. The drawback is that angiogenic factors incorporated within tends to leach
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out [130, 142].The resorption characteristics for polygalactin are comparable to individual
components but it generates a noticeable inflammatory response [133].
The PGA-PLA copolymer porosity, architecture and mechanical properties can be
controlled. [143]. The architecture can then guide cell seeding and distribution.
A number of polymers were investigated to control degradation rates. PGA/PHA
copolymer scaffold was used to enhance the mechanical properties of the construct as
well [144]. PHAs are naturally produced linear polyesters that can be biosynthesized by
a wide variety of microorganisms. These linear polyesters are degradable, biocompatible
and provide a reserve of carbon and energy. The PHAs degrade either by the
microorganism or by hydrolysis. They present a wide range of properties based on
composition, molecular weight and configuration [132]. The scaffold consists of PHA as
an outer layer and PGA as the inner layer. PHA was degraded simply by hydrolysis over
a period. PGA promotes cell attachment and tissue formation.

A mixture of ovine

endothelial cells, smooth muscle cells and fibroblasts were seeded simultaneously on
the lumen, allowed to attach and proliferate for 7 days prior to implantation. These grafts
exhibited patency up to 22 weeks while the acellular conduits used as control turn out to
be occluded from 1 day to 14 days. In addition to exhibiting long time patency there are
also limitations to this graft such as

high porosity, stiffness and a relatively short

degradation time. A similar approach has been used by using bovine and porcine cell
seeded PGA scaffold. The SMC seeded grafts were conditioned for 8 weeks under
pulsatile flow, which resulted in an organization of SMCs with oriented fibrils between
cells. The graft displayed a contractile response and the collagen content increased 5
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times that of a native artery [138]. The cellular penetration of these scaffolds is reliant on
the highly porous open configuration.
In addition to using PGA in combination with PHA, PGA was used with Poly-4hydroxybutyrate (P4HB) [145]. P4HB is a PHA with slightly higher stiffness and a
significant higher strength, comparable to those of ultra-high molecular weight
polyethylene. This biologically derived polymer was used independently as well as in
various combinations to generate tissue engineered vascular grafts [146-150]. These
constructs exhibited reasonable success having appropriate mechanical properties, but
problems relating to degradation time, degradation products as well as inflammatory
responses continued.
The addition of P4HB contributes to scaffold pliability, strength and a relative fast
degradation profile [151, 152].This polymer combination of scaffold was seeded with
myofibroblasts up to 10 days. It was visible that after 7 days; multiple layers are present
hence increasing the density of the cells in the construct. The mechanical behavior of
PGA/P4HB was distinguished by Thompson et al. [153] under hemodynamic forces that
represent the physiological and mechanical environment under which scaffolds are
essential to perform.
Later on [154] P4HB scaffold was used again. The scaffold was seeded initially
with SMC and consists of a pressure increase from 15 mmHg systolic and 10 mmHg
diastolic pressures to a final pressure of 60 mmHg systolic and 40 mmHg diastolic. After
14 days, EC were added on the last two days. The constructs showed confluent
colonization with vascular SMC, initial synthesis of GAGs, increase in protein content
and cellular in-growth.
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More recently, a PGA based copolymer with P(CL/LA) and a PLA based
copolymer with were used as P(CL/LA) as the first attempt to develop tissue engineered
grafts. PCL is semi crystalline polyester that degrades at much slower rate than other
aliphatic polyesters. PCL is flexible, easy to process, structurally and thermally stable
[155]. The PGA-P(CL/LA) or PLLA-P(CL/LA) confirmed initial mechanical properties to
be effective, initial burst pressure, suture retention strength and ultimate tensile strength
within the physiological ranges and exhibit greater elasticity than synthetic vascular graft
[156]. Even though their gradual degradation, these scaffolds exhibit no thrombus
formation over 6 weeks. Current studies of these materials are underway to better
understand them even though so far they demonstrate adequate porosity, biomechanical
properties and high biocompatibility.
One of the major concerns of biodegradable materials is the byproducts and
fragments of the degraded polymer that can cause adverse inflammatory responses. The
other concern is the rate of polymer degradation and tissue integration; hence, the
polymer serves as a temporary scaffold to allow proper architecture and mechanical
strength. It is expected for the polymer to degrade as ECM produced by the cells is
formed, which is very critical to the overall success of the implanted vascular graft.

5.3.1.3 Natural Biomaterials in Current Vascular Grafts
While synthetic polymers offer excellent mechanical properties, they lack the
bioactivity of natural polymers like collagen, decellularized matrix, chitosan, fibrin and
elastin. The natural biomaterials are composed of ECM proteins used for cell attachment
and growth, have desired shape and the strength of the materials derived from [119].

72
Due to their low inflammatory responses and cytotoxic responses, these materials
represent a valid alternative in tissue engineering. Scientists have focused their efforts
on exploring biological supports such as collagen, decellularized vascular matrix and cell
sheets.
In 1986, Weinberg and Bell developed a vascular graft using collagen type I
scaffold supported by a Dacron mesh [157].

For this approach to be successful, a

nondegradable synthetic reinforcement used introduces limitations to the biological
adaptation and vasoactivity. Cultured bovine ECs, SMCs and fibroblasts embedded with
denatured bovine collagen were used to construct a vascular graft. Their study provided
early data on the feasibility of creating layers with ECM components similar to those of
the blood vessel. The burst strength of the scaffold was proportional to the collagen
content, but the graft did not achieve mechanical strength expected. As a result, the nonenzymatic crosslinking of ECM was used as a strategy to enhance the strength of the
collagen matrix [158]. In native tissues, ECM proteins are known to release growth
factors [159].
Expanding on the work with collagen scaffolds, others have examined the use of
decellularized matrices from porcine tissue. Decellularized matrix scaffolds were
introduced to obtain a physiologic, matrix scaffold resembling the native artery. It
consists of biological materials that have been treated by either using enzymes such as
Trypsin and/or detergents. Nevertheless, decelluarized matrices are biodegradable and
provide a 3-D environment for cells to grow. The potential advantages include easy
accessibility from transplant tissue donors, avoidance of immunogenic issues, and
retention of the 3-D architecture and natural biological composition [99, 160, 161].
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Nevertheless, studies have demonstrated that the decellularization process disrupts the
extracellular matrix [162].
Decellularized matrix tubes were obtained by enzymatic cell extraction of native
arteries or by using sodium dodecyl sulfate (SDS). They were also achieved using
solvent extraction of the lipid component with partial digestion using proteases to remove
cells [159]. The current detergent-enzymatic procedures include: suspension in a
hypotonic solution containing protease inhibitors, high salt extraction using Triton X-100,
DNAse and RNAse and treatment with SDS [163]. The goal is to maintain the protein
structure removing all potentially immunogenic cells. Decellularized matrix remains
durable under arterial flow, resists vascular rejection, decreases antigenicity [164], allows
cell repopulation before degeneration of the scaffold occurs [165, 166]..
Badylak et al.[167] introduced the concept of small intestinal submucosa (SIS).
SIS was obtained from pigs, has the characteristics of an ideal tissue engineered
biomaterial and acts as a bioscaffold for remodeling of many body tissues. The small
intestinal submucosa has the suitable functions required for a remodeling scaffold in
tissue repair and can stimulate site specific remodeling [168, 169]. The usage of SIS in
fabricating a construct does not involve cell seeding prior to implantation. Although, SIS
has many characteristics ideal for construction of vascular grafts, it lacks rapid
endothelization. Inflammation and thrombogenicity are some characteristics that threaten
the long-term patency of this scaffold [168].
Later on,

Huynh et al.[170] showed that these grafts were fully endothelized

within 3 months by minimal chemically crosslinking the collagen layers to provide
mechanical strength while maintaining biocompatibility. DiMuzio on the other hand,
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showed that after 8 weeks of arterial flow the decellularized graft exhibits satisfactory
strength and supports cell repopulation. At the same time, Woods [168], confirmed that
by conditioning the surface of intestinal sub mucosa with HUVEC for 14 days, deposition
of human matrix proteins occurred.
The possible advantages of using decellularized matrices include preservation of
extracellular matrix for strength and cell attachment and avoiding problems such as poor
compliance and aneurismal degeneration. To reduce thrombogenicity of decellularized
vascular grafts, they were covalently linked with heparin [171]. The decellularized
heparin treated grafts were similar in compliance to fresh vessels, burst testing 10-fold
increase in physiological pressure and provide a substrate for heparin-binding growth
factors, which promotes cell infiltration, healing and remodeling.
About 10 years later after Weinberg and Bell developed a vascular graft using
collagen type I scaffold, L’Heureux and colleagues [172] investigated the concept of
using cells to form sheets. This refers to thin cell sheets generated in vitro using human
aortic tissue as the cell source. The harvested cell sheets were folded to form layered
sheets, which were grown further by mounting them onto frames. The sheets resemble
the native structure with confluent extracellular matrix enhanced with collagen fibers and
offer an incredible potential with no toxicity or inflammatory reactions.
Smooth muscle cells and fibroblasts were cultured to form sheets, which included
extracellular matrix that could be peeled off from the flask after being cultured for 30-day
period and wrapped around a tubular scaffold to produce the concentric layers of the
aorta. The result suggests high burst strength, positive surgical handling and functional
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endothelium.

SMCs were aligned circumferentially according to H& E stain and

produced a significant amount of ECM.
Similar to L’Heureux, a collagen based scaffold with adequate properties was
developed by directly assembling collagen and cells in a cylindrical geometry [173]. The
technique involves the use of a ventilated rotating tube allowing SMCs to grow in a
cylindrical collagen matrix. Compliance results show that this scaffold has enough
rigidity. An additional technique includes, using a construct-sleeve hybrid [174] where
the acellular support was constructed from collagen gel with diverse crosslinking agents
such as glutaraldehyde, ultraviolet irradiation and dehydrothermal treatment. The
sleeves were combined with cells in a second layer of collagen to form the hybrid.
In a collagen-based approach, scientists investigated further the concept of using
collagen

gel

as

a

substrate

for

cell

attachment

and

signaling.

Since in the past synthetic reinforcement was used to reinforce the collagen gel,
numerous researchers have attempted to develop collagen grafts without the use of
synthetic support. Crosslinking was used as a strategy to increase collagen strength, in
addition to reinforcement [175]. Reinforcement refers to addition of stronger components
to the collagen matrix.
Crosslinking of collagen with elastin either in water using EDC in combination with
NHS resulted in increased stiffness and the ability to preserve the open porous structure
[176]. Elastin has been characterized by its high durability and ability to deform
reversibly, hence being responsible for elasticity of the tissue. Reinforcement to the
collagen matrix included incorporating intact elastic into collagen based vascular grafts to
form hybrid systems that mimic the arterial physiology and exhibit improved mechanical
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properties [177]. Hybrid constructs exhibited increased tensile strength and linear
stiffness compared with pure collagen structures.
Given that collagen and elastin are ECM proteins, the collagen-elastin scaffold
provided a temporary support for the cells under pulsatile conditions until the cells
produced their own extracellular matrix. Collagen-elastin scaffold [178, 179] has
increased SMC proliferation, distribution and higher collagen mRNA expression. The
challenge of incorporating elastin into graft homogeneously remains.
In addition to constructing vascular graft from collagen, scientists explored the
idea of using fibrin as a promising candidate for improving graft properties [180]. Fibrin is
a gel-forming protein produced from the patients’ own blood.

Fibrin can easily be

fabricated into scaffolds and integrated with cells, without the potential risk of a foreign
body reaction. Cell enzymes can degrade it when no degradation inhibitors are used.
Fibrin can be easily infiltrated by cells, since most migrating cells locally activate the
fibrinolytic cascade. The advantage of using a fibrin-based scaffold is that it serves to
obtain an initial cell distribution, more efficient seeding and gives a compact tissue
structure enabling accumulation of extracellular matrix. Jockenhoevel et al. [181]
explored the idea of using fibrin gel as an alternative scaffold. To prevent the tissue from
shrinking a mechanical fixation of the gel with the 3-D microstructure culture plates and a
chemical fixation with poly-lysine was used. Results indicated that it produced a
complete autologous graft, which is moldable, and the degradation is controllable by the
use of aprotinin.
In addition to collagen, chitosan based scaffolds have been also studied [182].
Chitosan is a linear cationic natural biopolymer produced by alkaline N-deacetylation of
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chitin [183].It is a biodegradable and bioresorbable polymer and was hydrolyzed
enzymatically in vivo. Upon degradation, it releases amino sugars that are incorporated
in various metabolic pathways and elicits simply mild or negligible inflammatory reaction
following implantation, injection or ingestion under normal circumstances. Covering
chitosan scaffolds with heparin would reduce thrombogenicity. Heparin inhibits
proliferation of vascular SMCs and protects many heparin-binding growth factors. Gong
et al. showed that chitosan scaffolds have a degradation time of 2 months, enhanced cell
proliferation, proper swelling and enhanced suture retention strength. Further studies are
underway to determine and establish that chitosan is a very promising material for use
as a vascular graft.
Beyond the scientific and technical challenges, the natural derived vascular grafts
have to overcome the clinical impact in order to be commercially viable. The natural
materials described above offer some clear advantages but it also brings their own
distinct challenges and further research will be needed in this area.

5.3.3 Vascular Graft Seeding Background
Seeding cells into a matrix is integral to the formation of scaffold and is the first
step to establish a 3D culture [145, 184, 185].However, long-term cell viability in vascular
graft constructs is a limiting factor, as these cells have to remain viable. Seeding
requirements for three dimensional scaffolds include high yield to maximize the utilization
of donor cells and a spatially uniform distribution of viable cells [186] . Most current
approaches involve either static culture of the construct with a cell suspension or
dynamic intraluminal seeding within complex bioreactors.
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For any given scaffold, the initial seeding influences cell density, retention and
spatial distribution of cells within the scaffold. There are currently two categories for
seeding cells in a 3D matrix with aim of achieving uniform distribution: static [187-191]
and dynamic seeding [192]. Typically, for static seeding cells are laid on the luminal side
of the scaffold and allowed to infiltrate in the scaffold over time. The advantage of this
seeding is that mechanical forces such as shear stress do not potentially damage cells.
The disadvantage is that in case of thick scaffolds, the cell infiltration rates can be low,
resulting in poor loading and uneven distribution of cells.

Numerous reports have

indicated low seeding efficiencies [193] and nonuniform cell distributions [194, 195].
In the case of dynamic seeding, an external force is applied on the cells to allow
them to infiltrate the scaffold at a higher rate [196]. The primary advantage of this
seeding is that it allows good control, more homogeneous distribution of cells and
quantitative loading. The disadvantage is that the seeding process can be complex and
time consuming. Beyond seeding efficiency, the homogeneity of the cell distribution and
retention of cells affects the newly synthesized ECM. Cell retention and distribution
depend on the surface chemistry, pore size and interconnectivity of the pore network.
In the recent years, a rotational vacuum seeding technique was developed by
Nieponice et al. [186]. The seeding technique can incorporate a large number of cells in
a short period with an even distribution. The limitation is whether an endothelial layer can
be seeded on this scaffold.
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5.4 EXPERIMENTAL METHODS
5.4.1 Materials
Rat-tail collagen, type I was isolated from rat-tails and prepared in house [75].
GAGs used in this study include heparin from porcine intestinal mucosa (MW 15,000
g/mol) purchased from Celsus Laboratories (Cincinnati,OH) and dextran sulfate (MW
40,000 g/mol) purchased from Carbomer, Inc (San Diego, California). All other reagents
were obtained from Sigma (St. Louis, MO).

5.4.2 Methods
5.4.2.1 Scaffold Fabrication
The method used for scaffold fabrication in this work is a freeze/drying technique. It
involves altering the temperature gradient during the polymer solution freezing process.
The technique involves several steps:
I. Assembly of various parts of the mold (the mold is designed with two outer stainless
steel parts , two plug caps and inner silicone core);

(a) Schematic

(b) Actual Mold

Figure 5.1 Mold design for vascular graft fabrication (a) schematic; (b) actual mold.
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II. Injecting the solution into the annular space of the mold;
III. Freezing the mold with solution in isopropanol dry-ice bath (allows formation of ice
crystals).
IV. Lyophilization of the frozen assembly (ice crystals converted into vapor, sublimation
of solid to gas).
V. Removal of the scaffold assembly (leaves behind a porous matrix).

In order to facilitate easy removal from the mold, the outer stainless steel shell was
sectioned longitudinally in half. Sigmacote was used to coat the steel core. The inner
core of the mold consists of silicone tubing filled with silicone.
For initial experiments, the scaffold is highly porous and made of the amino
polysaccharide chitosan 1.5 wt% high molecular weight chitosan with 5 % blended and 5
% cross-linked collagen isolated from rat tail tendons. The mold was filled with the
chitosan-collagen solution mentioned and frozen in a methanol bath with addition of dry
ice at -70ºC for 3 hours then lyophilized for 24 hrs. The scaffold was neutralized in
series of ethanol, detached from the inner silicone tube and washed several times with
1X phosphate buffer solution (PBS).
For later experiments, the scaffold is made of 1.5 wt% percentage high molecular
weight chitosan. The lyophilized scaffold with inner silicone mold was primarily removed
from the outer stainless steel mold. The scaffold was immersed in 5 % ammonia for half
an hour for neutralization. After this step, the scaffold was detached from the inner
silicone mold and washed several times with 1X phosphate buffer solution.
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The surface morphology of the scaffold was examined using scanning electron
microscopy. Lyophilized scaffolds were sectioned at various planes using a scalpel blade
to avoid distortion of pores. The samples were then attached to the sample stubs with
glue and sputter coated prior to examination under a Hitachi S-2400 Scanning Electron
Microscopy (SEM). Imaging was conducted at 15-25 kV. Pore diameter estimates, pore
orientation as well as pore connectivity was obtained by analysis of digital SEM images
from section samples. Pore size measured using Sigma Scan Pro. Average pore size
was obtained after measuring the dimensions of 10 pores chosen at random in the
samples.

5.4.2.2 Treatment of Scaffold with Glycosaminoglycans
The neutralized scaffolds were crosslinked with heparin (HE) or carboxymethyl
dextran sulfate (CM-DXS) using carbodiimide chemistry.
For crosslinking scaffolds with heparin, 1.4 ml of 15mg/ml HE GAG in PBS and
2.67 mg of N-(3-Dimethylaminopropyl)-N’-ethylcarboiimide (EDC) solution in PBS were
reacted for 15 minutes. This activates the GAG. The activated GAG solution was then
poured onto the scaffold and derivatized dynamically at 15 ml/min. The solution was
reacted over a 16-hour period. For crosslinking scaffolds with CM-DXS, 2.25 ml of 40
mg/ml of CM-DXS in PBS and 4.31 mg of EDC were used.
Quantitative evaluation of the GAG onto the scaffold was completed using the
Safranin-O assay. The amount of unbound GAG was tested. The bound GAG was
determined by subtracting the unbound GAG tested from the GAG bound on the surface.
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Subsequently after the reaction is complete, the scaffolds were washed with 1X
PBS three times, one hour each. Similar procedure was followed by reacting chitosan
scaffolds with CM-DXS. The only difference is that, in case of HE 0.2 gm of GAG /1gm of
chitosan ratio was used, while for CM-DXS 1 gm of GAG/1gm of chitosan. These ratios
were based on the results obtained from cell interaction studies with various GAG
crosslinked chitosan and chitosan/collagen surfaces.
Once crosslinking occurred, scaffolds were soaked in 80 % ethanol overnight at 37º
C for sterilization. After this step, scaffolds were immersed in 100 % ethanol to hydrate.
The pure ethanol allowed faster evaporation of water upon the 6-hour freeze-drying
period. The dry scaffolds were used for cell seeding followed by a conditioning period in
the bioreactor system.

5.4.2.3 Tensile Testing
Stress-strain properties of scaffolds were determined using a tensile tester (Figure
5.2). A load cell of 100N was used. Dry scaffolds were cut into rings. The rings were then
cut open to obtain a long, flat sample oriented in the circumferential direction. Then, they
were soaked with distilled H2O. Each sample was mounted in the tensile clamps;
specimen length and width were then recorded with a dial caliper. The resulting stressstrain data were used to calculate the yield strain, yield stress for each scaffold type.
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Figure 5.2 Mechanical testing setup

5.4.2.4 Scaffold Seeding
Optimization of cell seeding in culturing is an important step for successful tissue
engineering of vascular grafts. In our project, we investigated several seeding techniques
such as static seeding and dynamic seeding with cell suspension and static seeding with
collagen gel. Prior to seeding, scaffolds were tied on both ends with sutures to
polycarbonate connectors having an outside diameter of 3/8 “, matching the inside
diameter of the vessels at the physiological pressure. Subsequently, scaffolds were
neutralized and washed in 1X PBS. SMCs from confluent cultures were detached using
0.125% (w/v) Trypsin /0.05% (w/v) EDTA. Cell concentrations were determined with
hematocytometer.

Static Seeding
For static seeding with cell suspension (Figure 5.3 a), chitosan scaffolds were
sterilized and washed with PBS. Prior to cell seeding, the scaffolds were immersed in
medium for 24 hours. After 24 hours, a 4 ml cell suspension of vascular SMC was
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seeded throughout the graft lumen per half-circumferential area twice every half an hour
using a pipette. The duration of this seeding was 2 hours.
For static seeding with collagen gel (Figure 5.3d), chitosan scaffolds were sterilized
in 80 % ethanol at 37°C immersed in 100 % ethanol an d lyophilized for 24 hours. The
scaffolds were plugged to limit axial flow. Subsequent to drying phase, the scaffolds
were seeded with porcine aortic SMC suspended in a collagen solution (2 mg
collagen/ml, pH 7.4).The cell-collagen suspension was allowed to gel within the scaffold
for 40 minutes at 37°C prior to immersion in culture m edium. The duration of seeding
was set to 10 minutes, after the scaffolds and the cell suspensions were prepared.

Dynamic Seeding
For direct perfusion of cell suspension through the pores of 3D scaffolds, a dynamic
seeding system (Figure 5.3b, c) was fabricated. The system contained of a bubble trap,
scaffold chamber and a pulsatile pump. The scaffold was connected within the seeding
chamber. Prior to adding the scaffold to the seeding chamber, it was tied at both ends
with connectors. The connector at the bottom end was closed. Flow of the cell
suspension was induced by opening the bubble trap and dumping the cell suspension
into it. The cell suspension was moved through the scaffold with the use of a pulsatile
pump and the flow was regulated using a flow meter. Because the scaffold was
connected to the system efficiently, the cell suspension could not deviate around the
scaffold and forced to flow throughout the pores.
Vascular smooth muscle cells were seeded at a density of 60 million cells for 0.864
cm3. The cell slurry was diluted to 20 ml culture medium. Prior to adding the suspension,

85
the scaffold was attached to the setup and the system was filled with

MCDB 131

supplemented with 50 mg/ml amphotericin B, 50 ng/ml FGF-2, 10 ng/ml EGF, and 0.5
U/ml insulin, 10 % FBS and 100 U/ml penicillin and 100 U/ml streptomycin.
Subsequently, the cell suspension was added through a top opening on the bubble trap
and the bottom connector of the scaffold was completely closed. Thus, cells penetrated
through the walls, with medium exiting the scaffold radially. The system was run for 30
min at a flow of 50 ml/min. The scaffolds were then unhooked from the system and
placed in a 100 mm plate filled with medium and placed in an incubator (37 ºC and 5%
CO2) and rotated 90º around the longitudinal axis every 30–60 minutes for the first 1
hour to promote homogeneous cell adhesion in the scaffolds. Finally, cells were allowed
to adhere statically.

(a)
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(b)

(c)
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(d)
Figure 5.3 (a) Static seeding with suspension; (b) Dynamic seeding diagram;
(c) Dynamic seeding actual setup; (d) Static seeding with collagen gel.

In order to test the effectiveness of seeding methods, sections of the cell-seeded
scaffolds were attained. 10 % buffered formalin was used to fix the scaffolds, which were
then dehydrated and embedded in paraffin. Upon embedding, the blocks were sectioned
into 8-10 µm slices. The slices were stained with Hematoxylin and Eosin (H&E).

5.5 RESULTS
5.5.1 Scaffold Fabrication and GAG Derivatization
The scaffold was generated using the mold geometry presented in Figure 5.4. The
graft obtained has dimensions of 12-13 mm inner diameter and 60-70 mm length.
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Figure 5.4 Photographic images of scaffolds

After the fabrication of scaffolds, scaffold derivatization was performed using a
proposed dynamic system (Figure 5.5). The system was comprised of a scaffold
chamber, bubble trap and a peristaltic pump. The activated EDC-GAG solution was
injected into the bubble trap and then the solution was circulated throughout the system
at 15 ml/min for 16 hours.

Figure 5.5 GAG derivatization setup (a) entire setup (image on the left) ; (b) enlarged view of
scaffold (image on the right).

5.5.2 SEM Images of Scaffold
SEM images visibly showed the porous nature of the scaffold. The pores are very well
connected which is critical for nutrient supply as well as cellular entrapment.
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By means of the method presented earlier, directional ice crystals were formed during
freezing (See Figure 5.6). For initial experiments, scaffolds were fabricated using 1.5 g of
chitosan and 0.166 g collagen in 100 ml. The preparation of chitosan-collagen solution
was presented in earlier chapters. Scanning electron microscopy displayed pore size
ranging from 10-15 µm for the outer surface of this scaffold and around 200 µm for the
luminal surface of the scaffold. Blended chitosan-collagen scaffolds had unreliable
surface porosity; hence, for later experiments the collagen was excluded from the
material composition.

Figure 5.6 SEM of a chitosan/collagen scaffold with 3 % acetic acid. Collagen portion is blended
and crosslinked into chitosan. (a) Inner portion; (b) Outer portion; Bar =100 µm

For later experiments, collagen was removed from the material and only 1.5 wt %
chitosan scaffolds were used (see Figure 5.7). Absence of collagen allows for better
interconnectivity of the pores and more homogeneous pore size. Larger pores were
obtained for both the luminal surface and outer surface for chitosan scaffolds. These
scaffolds exhibited an outer porosity ranging from with mean of 79.83 + 17.67 µm
(N =37) and an inner porosity ranging from 237.24 + 80.55 µm (N=37).

90

Figure 5.7: SEM of 1.5 wt% high molecular weight chitosan scaffold with 3 % acetic acid
concentration (a) Inner portion; (b) Outer portion ; Bar = 200 µm

5.5.3 Tensile Testing
Porous chitosan scaffolds exhibit reduced mechanical strength compared to nonchitosan materials. The evaluation of the scaffolding material can give a base strength
values for starting materials prior to cellular growth.
The unseeded chitosan-collagen and chitosan scaffolds exhibit ultimate tensile strength
as presented in the Table 2 below. The overall tensile strength of chitosan material is
around 24x 103Pa, whereas for the material where collagen is present it is only 13x
103Pa (Figure 5.8). Addition of collagen into the scaffolds diminishes the elastic modulus
of the scaffold, consequently suggesting that crosslinking and blending collagen
weakens the mechanical properties of the scaffold even though the differences in
mechanical properties between chitosan and chitosan/collagen scaffold are not
significant.
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Figure 5.8 Ultimate tensile strength of chitosan-collagen in comparison with chitosan material.

Mechanical Properties

Chitosan-Collagen

Chitosan

Ultimate Strength (kPa)

13.78 + 1.41

24.81 + 4.76

Ultimate Strain (%)

0.95 + 0.13

0.50 + 0.05

Elastic Modulus (kPa)

25.25 + 2.01

29 + 5.65

Table 2. Mechanical properties of unseeded scaffolds

The three dimensional architecture of the pores, pores size and overall material
porosity contributes to decrease in mechanical properties. The crosslinking modification
of chitosan diminishes the strength of the scaffold at the same time. The culture of SMC
is expected to enhance the mechanical properties of the vascular graft.
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5.5.4 Scaffold Seeding
Desirable features for any seeding techniques include uniform cell distribution,
seeding efficiency, high reproducibility and user independence. The vascular seeding
methods developed for the purpose of our study include simple technique such as static
seeding to complex such as dynamic seeding. Static seeding occurs when cells and
scaffold are brought into direct contact. The cells are allowed to sit relatively undisturbed
to attach and migrate into scaffolds. Dynamic seeding involves allowing medium flow
with cells within the scaffold pores. The cells were trapped within the scaffold.
Three seeding methods were used to seed SMC onto chitosan vascular graft. In
the static seeding with cell medium suspension, 4 ml of cell suspension containing 22 x
106 SMC cells were seeded onto 0.864 cm3 scaffold in tissue culture plates. The entire
seeding lasted up to an hour, after which 8 ml of culture medium was added. In the
static method with collagen gel, 4 ml of 2 mg/ml collagen gel mixed with 100 x 106 SMC
cells was added to dry scaffolds ( V =0.864 cm3 ) in tissue culture plates. In the dynamic
seeding method, 5 ml of cell suspension containing 28 x 106 cells were added to 70 ml of
medium already present in the perfusion system. The system then run for 30 min at 30
ml/min. Seeding efficiencies was determined by comparing the number of cells adherent
to the matrices to that of the cells remaining in the seeding solution.
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Seeding Type

% Seeded

Difficulty

Static-Suspension

60

Easy

Static- Collagen Gel

94

Easy

Dynamic

93

Difficult

Table 2. Comparison of cell seeding methods

In static seeded scaffolds with only cell suspensions and dynamic seeded
scaffolds with cells suspensions, samples were taken at later date to allow a longer
period to secure cell attachment on the surface before connection to the bioreactor
system. Static seeded scaffolds rely on diffusion of cells whereas dynamic ones rely on
forcing the cells through the pores. Image analysis of the cross sections demonstrated

Lumen

cells are mainly present on the luminal side with minimal infiltration within the scaffold.

(a)

Lumen

94

(b)
Figure 5.9 H& E stain (a) statically seeded scaffold; (b) dynamic seeded scaffold

Construct cellularity increased when SMCs cells were seeded in collagen gel and
the cell distribution became more spatially uniform. The chitosan scaffolds seeded with
the static seeding method using collagen gel displayed cells 800 µm into the scaffold
(Figure 5.10). Image analysis of the cross sections demonstrated that more cellular
infiltration through the radially open pores. Image analysis established that on day of
seeding individual cells are present into the scaffold.
Hematoxlin & Eosin staining of the collagen gel seeded scaffolds indicates
uniformity while in static and dynamic seeding with medium suspension cells are
predominantly existent on the luminal surface with minimal penetration within the scaffold
(see Figure 5.10).

Lumen
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(a)

(b)
Figure 5.10 H& E stain of statically seeded chitosan scaffold with collagen gel (a) sectional view;
6
(b) enlarged view. The scaffold was seeded with 100 x 10 SMC cells embedded in 2 mg/ml chitosan
gel. Bar = 200 µm
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5.6 DISCUSSION
The search of biomaterial as a scaffold to mimic blood vessel morphology and
mechanics has become increasingly important with increase occurrence of vascular
diseases and poor long-term patency of the current vascular graft [197]. In this study,
chitosan-collagen and chitosan scaffolds were fabricated by crosslinking and freezedrying technique.
The porous nature of the mold by freeze-drying of pre-gelled chitosan solution
allows the chitosan solution to enter the pores strengthening the bond between the two
[198]. As a result, Sigmacote was used to allow efficient scaffold removal from the outer
shell and the inner silicone core was afterward removed from the silicone with 5 %
ammonium or 100 % ethanol.
Earlier studies indicate that scaffolds are fundamental in obtaining tissue
reconstruction and provide the structural integrity until the cells fabricate their own
extracellular matrix [199]. It is crucial for vascular scaffolds to have a high porosity,
adequate pore size and have biodegradable properties [198]. In addition, the
biodegradability of the scaffold has to be at the same rate as the tissue formation.
Upon removal from the mold, scanning electron microscopy was used to
characterize the vascular scaffold and determine the pore size and interconnectivity of
these pores. Adequate pore size is essential for cellular entrapment. If the pore sizes
were too large, substantial amount of cells would pass through the scaffold resulting in
poor seeding. On the other hand, if the pore sizes were too small they would not allow
cells penetration within the scaffold. In addition, reduced or nonexistent connectivity
between pores would lead to poor cell seeding and inadequate nutrient transport in
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regions of no connectivity. Cell viability and proliferation are taken into consideration, to
support since lack of nutrients within the scaffold leads to cell death [197].
The vascular scaffolds formed from chitosan-collagen used in our study showed
reduced pore connectivity. It is evident that crosslinking of collagen to chitosan
diminishes the strength of the vascular scaffold and produces inconsistent porosity. The
luminal pore size for the collagen-chitosan scaffold was around 200 µm and the outer
surface was around 10 µm. Even though, the inner pore size was adequate for
suspension static seeding, but the outer pores were too large to effectively retain cells
within the scaffold. The pore connectivity was also low. As a result, collagen was
eliminated from the scaffold composition.
Despite eliminating collagen from the scaffold composition, collagen was still
present at the time of seeding. Fabrication of chitosan vascular structures with good
interconnectivity and porosity are obtained due to the low degree of N-acetylation of
chitosan [200]. The cell seeding method was determined to be critical not only for density
of cells initially adherent but also to the quality of the tissue obtained. Desirable features
for any seeding technique included: preserving cell viability, providing a uniform cell
distribution and attaining a high seeding efficiency with reduced seeding time. The
homogeneous porosity of the chitosan scaffolds increased cell retention in cell-collagen
gel static seeding.
The matrices static seeded with only cell suspensions resulted in a low cellularity
in the center and uneven cell distribution of the tissue constructs. With cell suspension
static seeding, most cells were present near the luminal surface. This can be explained
by the fact that cells infiltrated the scaffold into lower numbers and present only at the
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luminal surface because cell leakage from the scaffold. The technique resulted in low
numbers of cells at initial seeding.
Upon this conclusion, we decided to use collagen gel mixed with cells to
determine to increase the amount of cells trapped into the scaffold. However, the static
seeding with cell-collagen gel suspension yielded a larger number of adherent cells
trapped within the scaffold. To our knowledge, the present study is the first to investigate
the cell-collagen gel seeding into a chitosan scaffold. This type of seeding exhibited 94
% in comparison to 60 % seeding efficiency obtained with cell-suspension.
Previous research indicated that collagen gel scaffolds were used in the
construction of arterial grafts [158], which made use of collagen gel approach a viable
option for seeding cells. However, our technique increases cell retention within the
scaffold as well as cell attachment and proliferation. The technique is far more
advantageous than static seeding and dynamic seeding with cell-medium suspension
where the cell retention was considerably lower. The technique addresses a deficiency in
the current cell seeding techniques and may ultimately lead to uniform cell distribution.
Based on the results, our chitosan graft was seeded with 2 mg/ml collagen type I
gel; static collagen-gel seeding being an effective and simple method for seeding
vascular grafts.

5.7 RECOMMENDATIONS
Even though, the addition of collagen gel improves vascular graft seeding under
static conditions further optimization of the cell seeding is required. The use of biological
molecules such as glycosaminoglycan within scaffold composition should be added in
combination with chemical cross linkers to increase cell proliferation and mechanical

99
properties. The positive aspect of using glycosaminoglycan in addition to collagenseeded scaffold should be tested under cyclic testing imposed by the bioreactor to the
vascular construct and tested for cell viability in the bioreactor.

100

Chapter 6
BIOREACTOR DESIGN AND OPERATION

6.1 INTRODUCTION
The solution to engineer 3-D tissue substitutes involves a dynamic system such
as a bioreactor. A bioreactor can be defined as an apparatus that can mimic
physiological conditions in order to regulate cell seeding, growth and construct
maturation in a cost efficient manner [138, 201, 202]. Bioreactors can be custom
designed to engineer tissues with complicated 3-D geometry containing multiple cell
types. Cell alignment is vital to the strength and properties of the vessels and can
influence cell growth direction.
Consequently, bioreactors have been developed for the dynamic mechanical stimulation
of tissue engineered (TE) cardiovascular constructs like vascular grafts, myocardial
patches and heart valves [203]. The requirements for developing a bioreactor include (i)
control the physiochemical environment, (ii) facilitate monitoring of cell/tissue quality, (iii)
facilitate cellular distribution and organization in developing scaffolds, (iv) maintain a high
degree of environmental reproducibility, (v) make efficient use of growth factors and
medium components, (vi) ensure tissues have proper nutrient and waste mass transfer,
(vii) minimize scaffold handling and (viii) facilitate removal of metabolites [204].

In

addition to these, additional requirements such as generation of pulsatile forces,
pressures, flow velocities, shear stresses and pulse frequencies may be extremely
important design considerations [205] . The following sections will discuss the concept,
design and development of the bioreactor system used in the current project.
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6.2 SPECIFIC AIMS
The working hypothesis for this part of the project was that a pulsatile dynamic
environment, efficient cell entrapment, distribution, and initial presence of extracellular
matrix proteins at seeding are important features for obtaining a viable vascular graft. In
order to test this hypothesis, specific aim 3 was established. The specific aim 3 was to
develop a 3D bioreactor environment for cell conditioning in order to facilitate long-term
functionality, distribution, proliferation, ECM deposition and viability of cells in the
construct. In this phase we evaluated a continuous and pulsatile setup using scaffold
seeded smooth muscle cells as well as scaffolds seeded with a co-culture of smooth
muscle and endothelial cells.

6.3 BACKGROUND
Over the past three decades, researchers have tried to design in vitro systems
that would permit them to develop functional 3D vascular grafts. The major challenge of
the system is simulating the physiological environment for creating ideal in-vitro
conditions, having enough nutrients and waste exchange between cells and their
surroundings, and generating a functional non-thrombogenic endothelial layer
To develop a blood vessel substitute, Niklason et al. [206] cultured PGA
constructs in a pulsatile bioreactor. The bioreactor was based on the concept that
physical stimuli improve cell and tissue growth [205]. The pulsatile reactor generated 165
beats/min and 5 % radial strain by means of superimposed pulsatile flow. It incorporated
a number of seeded vascular scaffolds conditioned in parallel under pulsatile flow. The
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culture medium contained ascorbic acid, copper sulfate, alanine, glycine and 20% fetal
bovine serum to ensure proper biochemical stimulation.
Hoerstrup et al. [146] developed a pulsatile perfusion bioreactor similar to the
heart valve design [207] already developed with minor modifications which allows
multiple seeded vascular grafts in parallel. The system exhibits a pulsatile flow through
the lumen from 125 ml/min to 750 ml/min, hence generating shear stress to the luminal
surface.
Pulsatile flow is not the only stimulation that has been used in the formation of
engineered vascular grafts. Seliktar et al. [208] designed a bioreactor to apply cyclic
strain to the scaffolds. The tissue-engineered vessel was exposed to dynamic
conditioning through inflation and deflation of the conduits at 1 Hz frequency. These
grafts are cultured over thin walled silicone tubes, which are inflated with culture medium
under pneumatic control to produce cyclic distension of 10 %.

The cyclic strain

enhanced cell morphology and attachment. The main disadvantage is lack of pulsatile
flow inside the luminal side.
To advance the formation of extracellular matrix, different stimuli have been used.
Peng et al. [209] used both cyclic stretching and pulsatile flow with perfusion to culture
vascular cells. In this design, endothelial cells added on top of vascular cells were
exposed to pulse pressures and shear stresses comparable to the physiological values.
It was observed that cells aligned in the direction of higher pulsation and parallel to the
flow.
Further advancement to the Hoestrup bioreactor design was developed by Sodian
[210]. They included an additional chamber used for seeding where the construct was
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surrounded continuously by media. The flows rates used range from 100 mL/min to 3
L/min with shear stress of 1.12 to 32.45 dyne/cm2.
Current methods to induce pulsatile flow into the bioreactor is limited, Thompson
et al.[153] created a bioreactor using a mechanical ventilator to induce pulsatile, laminar
flow into the column to mimic mammalian physiology. The vascular constructs contain
semi-compliant tubing to enhance the circumferential stretch. One of the advantages of
this concept is that medium exchange and pressure monitoring occurs by using a oneway valve further from the construct.
Researchers continue to optimize the cell seeding and culturing of vascular
conduits. In 2003, the concept of dynamic rotational seeding and cell culture for vascular
tube formation was introduced [211]. In this system, the constructs are partially rotated
with even distribution of shear stress and medium velocity. The major limitation of this
system includes the absence of gas exchange hence requiring daily medium changes.
The advantage of the system is that it enhances cell growth, uniform distribution of shear
stresses, and culture medium velocity for both outer and inner surfaces of the scaffolds.
Nasseri Mironov et al. [212] developed a system that included two perfusion
systems in which longitudinal strain was an important element. The perfusion bioreactor
developed included two perfusion systems: one for inside perfusion and one for the
outside. The longitudinal stresses were applied on the outer side of the construct. This
type of stress-accelerated tissue engineered vascular wall maturation and resulted in a
tissue engineered vascular graft. The advantage of this model is that it allowed control of
flow rate, pressure and longitudinal strain to optimize mechanical properties.
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Later on, Williams and Wick [203] explored the sequential seeding of smooth
muscle and endothelial cells under biomechanical simulation of the system using porous
nonwoven PGA scaffold. In this case, the scaffold was held in place by cable ties and
mounted between glass tubes. Peristaltic pumps pumped medium through the lumen
and along the external surface at a flow of 40 ml/min at 1Hz. The main rationale of using
external flow was to provide nutrients to the outside surface of the construct. This system
promoted cell proliferation by regulating the mechanical and nutrient environment,
promoted matrix deposition on the inner and outer surface of the scaffold by dual
perfusion and maintenance of sterile conditions. The disadvantage was that cell
proliferation and matrix deposition reduced the porosity of the scaffold and diminished
nutrient transport.
McCulloch et al. [213] saw the need to develop a bioreactor system capable of
delivering a series of stimuli. The bioreactor designed mimicked the pressure and strain
environment found at the aortic root. At the same time, it had the capability for integral
perfusion as well as long-term culture ability. The advantage of this concept was that the
scaffolds conditioned had a variety of flow, force and pressure variations.
Narita et al. [214] and McFetridge et al.[215] further investigated the effect of
pulsatile flow in vascular graft bioreactors. Narita demonstrated that pulsatile flow
enhances production of extracellular matrix. On the other hand, McFetridge showed that
ex-vivo vascular tissue seeded with smooth muscle cells under pulsatile flow conditions
could guide multiple layers of cells to adhere to the scaffold.
Mironov’s idea of using both pulsatile and longitudinal flow was re-evaluated by
Bilodeau et al. [216]. Bilodeau et al. designed a bioreactor to stimulate the regeneration
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of the arterial tissue. The horizontal position of the construct within the system and
rotation ensured the uniformity of cell growth and cell spreading. The benefit of this
reactor was the ability to investigate mechanical properties.
Recently, Iwaski et al. [217] developed a system consisting of a ventricular model,
a compliant silicone tube, a peripheral unit, a gas exchange unit and a chamber to mount
the engineered vessel. The bioreactor culture regulated flow from 0.2 to 0.6 L/min and
pressures from 20 to 100 mmHg. The benefit of the reactor was that the engineered
vessel has extensive production of elastin and collagen as well as similar elastin
characteristics as native arteries.
In general, the current research focuses on developing bioreactors that encourage
vascular cells to grow in an organized fashion to regenerate tissue. The focus of all
studies was to apply mechanical stresses to scaffold during construct maturation to
encourage cells to self-assemble and provide a fruitful environment for extracellular
matrix deposition.

6.4 EXPERIMENTAL METHODS
6.4.1 Materials
MCDB 131, Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum
(FBS), trypsin-EDTA, ascorbic acid, insulin, retinoic acid, bovine albumin, penicillinstreptomycin, Chloramine T Reagent, n-propanol, and Eldrich’s Reagent were purchased
from Sigma-Aldrich (St. Louis, MO), 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide
(EDC), hydroxyproline, sodium acetate, glacial acetic acid, sodium hydroxide, perchloric
acid, were purchased from BioChemika (Fluka). Calcein red-orange was purchased from
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Invitrogen (Carlsbad, CA). Hematoxylin and Eosin and Masson’s Trichrome stain were
from VWR (Chicago, IL).

6.4.2 Methods
6.4.2.1 Bioreactor Design and Fabrication
The design of the bioreactor consisted in establishing the best structure to
assemble the cells as well as the housing to culture and monitor the tissue. In order to
meet the desired functions we developed a vascular graft bioreactor (Figure 6.1). The
developed perfusion chamber was made of glass and completely transparent. This
system offers the most desired features needed in an ideal bioreactor. Aside from that, it
can induce different levels of pulsatile flow in controlled conditions.
The main components of the system included scaffold culture chambers II, a
bubble trap and a medium reservoir and I. Culture chambers II and I were connected
separately to the bubble trap with medium flowing directly through the scaffolds. The
chambers were made of glass with tubing made of silicone. The construct chambers
have an outer diameter of 28.41 mm and a length of 140 mm. Scaffold was kept in place
with ties tied around connectors in turn connects to the seeding chambers. For seeding
purposes, a connector closure blocks the exit of the connector.
Within the system, culture medium flows down through the scaffold and then up
along the outer scaffold surface. The exit from the culture chamber was on the side near
the inlet connector at the top. The exits from chambers II and I were connected to a Y
connector, which was subsequently connected to the medium reservoir. The reservoir
chamber serves a double function as a medium reservoir and as a medium oxygenation
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chamber. Apart from the medium inlet an outlet tubes connected to the reservoir, a
separate, 1.5 mm diameter silicone tubing with its own inlet and outlet connections sits
within the reservoir was at that juncture connected to the air/CO2 supply. Oxygen and
CO2 penetrates the system via diffusion through the silicone tubing.
A positive displacement pump was use to adjust the adjusted the low rate. The
pump contained a rotor with several rollers is attached to the external circumference that
compresses the flexible tube fitted inside the pump casting that contains the fluid. As the
rotor turns, the tube under compression closes forcing the fluid to circulate, thus moving
through the tube. As the tube opens to its natural state after passing rotors, fluid flow
was induced to the pump.
By adjusting the pump stroke rate and stroke volume, flows ranging from 0 - 1000
ml/min can be used. The flow rates are somewhat low as compared to the physiological
flow rate which varies anywhere in the range of 550 ml/min to 1.6 L/min in the age group
of 6-28 months having a weight of 4-15 lbs. and height in range of 1-2.5 ft.
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Bubble Trap

Construct
Chambers

Pump

Reservoir/Oxygena

Incubator

(a)

(b)
Figure 6.1: Bioreactor system and setup (a) schematic; (b) actual view.
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6.4.2.2 Cell Culture
The bioreactor and cell culture medium was based on MCDB 131 medium
supplemented with amphotericin B, 50 ng/ml fibroblast growth factor 2 (bovine pituitary),
10 ng/ml epidermal growth factor (mouse sub-maxillary glands),10 % fetal bovine serum
,100 U/ml penicillin and 100 U/ml streptomycin and 50 mg/ml gentamycin. For good
tissue development, 0.3 mM ascorbic acid 2-phosphate and 0.1 mM retinoic acid were
further added to the medium every 3 days.
The smooth muscle and endothelial cells used in these experiments were
harvested as presented in Chapter 4. Prior to scaffold seeding, the smooth muscle cell
population was expanded in MCDB131 with amphotrecin B, 50 ng/ml b-fibroblast growth
factor (bovine pituitary), 10 ng/ml epidermal growth factor (mouse sub- maxillary glands),
10 % fetal bovine serum and 100 U/ml penicillin-streptomycin.
The cells were cultured in a 37°C, 5% CO 2 incubator to promote their growth.
Medium change was performed on the second day after seeding and then subsequently
every 48 hours until the cells were used. Cells were observed under the phase contrast
microscope (40X – 400X total magnification) to ensure healthy growth. After two weeks
in primary culture, prior to reaching confluence the cells were passaged using trypsinEDTA. The cell suspension was homogenized thoroughly with a micropipette and
aliquots of 10 µl were used for counting on a hemocytometer. The cells were futher
mixed with 2 mg/ml collagen gel and seeded into the vascular grafts. Collagen gel used
was prepared using 9 ml of 3.9 mg/ml collagen gel type I to 1 ml of 10x DMEM.
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6.4.2.3 Bioreactor Cultures
In order to provide adequate nutrient supply and gas exchange to our chitosan
constructs, we used a perfusion bioreactor system. Evaluation of the cultured construct
is essential in any tissue-engineered graft. The evaluation provides an overview of
cellular arrangement, distribution, viability and extracellular matrix production. In total, 12
bioreactors were run. Some of the initial cultures failed due to seeding techniques as well
as material selection, while others failed due to contamination issues. In the initial
bioreactor cultures, we observed such as:
(a) Low cell penetration in the scaffold when static seeding was used;
(b) Dynamic seeding alone is not efficient due to difference in pore direction and
non-homogeneous seeding;
(c) Lack of ECM protein into the scaffold at seeding diminishes cell viability;
(d) Heparin was not the best GAG to be used in 3D conditions due to possible
leak into the medium;
(e) Continuous flow is not preferable for SMC culture and alignment.
Consequently, results and discussion involves only three bioreactors. The
following sections give details on the experiments as well as discussions involving the
construct.

Bioreactor I
The scaffold used in this bioreactor system was cross-linked with carboxymethyl dextran
sulfate (refer to Chapter 5 Scaffold Fabrication and Seeding). The scaffold was tied to
connectors using ties. One of the connectors was blocked to eliminate leak of the
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collagen gel-cell suspension from the graft longitudinally. For seeding cells, the scaffold
was placed horizontally on cell culture plates and 4 ml of a mixture of cell suspension
and 2 mg/ml collagen type I gel was applied to the to the cylindrical portion of the
scaffold. (Note: The dry scaffold was initially cylindrical. As soon as the cell suspensioncollagen gel mixture was applied, the scaffold softened and flattened. Seeding was
conducted for 15 minutes with approximately 94 million smooth muscle cells seeded into
the scaffold. The scaffold was rotated 90° about its ax is every time the suspension was
applied. After gelation, culture medium was added and the vascular construct was
placed into static culture for 24 hours. After this time, the closure was removed scaffold
and it was subsequently mounted in the bioreactor system. (For further details on the
scaffold mounting assembly, refer to the bioreactor design.) The construct was
suspended upright from the connector at the top/inlet of the culture chamber and
perfusion cultured for a period of 20 days. The culture medium volume used was
approximately 600 ml. The bioreactor was run under continuous flow at 50 ml/min and
flow rate increased up to 150 ml/min. Construct graft samples were excised on days 7,
11, and 20.

Bioreactor II
The carboxymethylated-dextran sulfate chitosan scaffold was used for this bioreactor.
Scaffolds used in this bioreactor system were neutralized with 5% ammonia, derivatized
with GAG and lyophilized for 24 hours. The scaffold was set in a tissue culture plate and
seeded with 80 million smooth muscle cells mixed with 2 mg/ml collagen type I gel. The
construct was turned 90° every time the cell- gel mixture was added. After gelation,
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culture medium was added and the seeded scaffold was static cultured for 24 hours.
Once this time passed, the construct was mounted in the bioreactor system. The
construct was perfusion cultured for a period of 16 days. The medium volume used was
approximately 600 ml. The bioreactor was run initially in continuous flow conditions at 50
ml/min. The flow was then changed to pulsatile flow of 200ml/min and 33 beats per min
after 3 days. During culture, the medium change took place every 3 days. Excised graft
samples from days 7 and day 13 of culture for evaluation.

Bioreactor III
The vascular graft used for this bioreactor had similar biologic composition to the scaffold
used previously in bioreactor II (refer to Chapter 5 Scaffold Fabrication and Seeding).
For seeding cells, the scaffold was prepared as presented in earlier reactors and also
neutralized with 5% ammonia, derivatized with CM-dextran sulfate and vacuum dried in
the lyophilized for 24 hours. The vacuum dry scaffold was placed into a tissue culture
dish for storage prior to seeding.
Prior to the seeding procedure, 89 million smooth muscle cells were trypsinized
from their plates. The trypsinzed smooth muscle cells were re-suspended in 4 ml of 2
mg/ml collagen type I gel mixture and seeded into the scaffold as described previously.
After gelation (~45 minutes), 4 million aortic endothelial cells were seeded in a 1 mg/ml
collagen gel mixture. The construct was static cultured for 24 hours in a 37°C, 5% CO 2
incubator. On day 2, the construct was transferred into the bioreactor system and
perfusion cultured for a period of 15 days with medium changes every 3 days. The
bioreactor system was started under pulsatile conditions at 300 ml/min with 37
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beats/min. Samples were excised on days 5 and 14 from the construct in order to be
evaluated.

6.4.2.4 Cell Viability
Long-term viability of cells is necessary for the seeded scaffold to remodel itself
into viable, patent vessel. Standard fluorescence assays were employed to evaluate cell
viability. Calcein Red-Orange assay (Invitrogen) was then used. Tissue pieces were
excised from the culture construct and washed several times with DMEM without phenol
red. Then, the tissue was incubated in a 1:1000 dilution of calcein red-orange solution in
DMEM. The dye solution was aspirated after 20 minutes and the sample were washed
with DMEM once. Lastly, fluorescence microscopy was performed to capture fluorescent
images of the live cells.

6.4.2.5 Histology
The 4-Hydroxyproline assay [218] was performed to evaluate the amount of
collagen secreted into the medium as well as collagen deposited into the cultured
construct. This assay involves a hyydroxyproline (Hyp) stock solution at a final
concentration of 0.1 mg/ml in distilled water [219, 220]. Acetate-Citrate Buffer (pH 6.5)
was then prepared by dissolving 12 g of sodium acetatetrihydrate, 4.6 g of citric acid, 1.2
ml of glacial acetic acid and 3.4 g of sodium hydroxide in distilled waterand the solution
volume was made up to 100 ml.
Chloramine T Reagent (0.056M) was prepared by dissolving 0.127 g of
Chloramine T in 2 ml of 50% n-propanol in distilled water and was adjusted to 10 ml with
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acetate citrate buffer. Ehrlich’s Reagent (1M) was prepared by dissolving 1.5 g of pdimethylaminobenzaldehyde in 10 ml of n-propanol/perchloric acid (2:1 v/v). 2 M sodium
hydroxide (NaOH) solution was prepared by dissolving 8 g of NaOH in 100ml of distilled
water.
The medium samples (25 ml of culture medium obtained from bioreactor medium
change) was then frozen in liquid nitrogen and lyophilized until dry (36-48 hrs). The
lyophilized samples were then ground to obtain a fine powder and 0.1 g of this powder
was subsequently dissolved in 0.5 ml of distilled water.
The graft/tissue samples were weighted, washed and then frozen in liquid
nitrogen. The tissue samples was lyophilized and grounded to a fine powder. The
powder was then dissolved in distilled water.
Standard solutions were prepared by diluting the 0.1mg/ml Hyp stock solution in 2
M NaOH to give a final concentration of 0, 5, 10, 15, 25 µg/ml of Hyp solution. 50 µl of
each standard solution were taken in 5 ml screw capped glass vial. At the same time,
medium samples were diluted by adding 40 µl of 2 M NaOH to 10 µl of the concentrated
medium solution. In case of scaffold samples, the pieces were directly soaked in 2M
NaOH. These samples were hydrolyzed by autoclaving at 120° C for 20 minutes. To the
hydrolyzed samples 450 µl of the Chloramine T was added, mixed gently and then the
oxidation was allowed to proceed for 25 minutes. To these samples 500 µl of Ehrlich’s
reagent was added, mixed gently and the chromophore was allowed to develop by
incubating them at 65 °C for 20 minutes. Then, the sam ples were cooled at room
temperature and their absorbance was read using UV Spectrophotometer Spectra Max
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250 from Molecular Devices. The sample volume used for the test was 150 µl at an
absorbance of 560 nm in the Endpoint Mode.
Initially, the medium volume used during each medium change in the bioreactor
culture was obtained. Then based on the weight of 25 ml of dried medium powder of the
medium change, collagen content was calculated. For weight calculations, amount of
hydroxyproline was evaluated using the equation obtained from the standard curve.
Finally, the collagen amount was determined by multiplying the hydroxyproline mass by
24. The cumulative collagen content, final amount of collagen if no medium was removed
from the bioreactor was plotted against the number of days in the case of the medium
samples.
For evaluating collagen in the scaffold, initial dry weights of the specimen were
noted down. Then similar procedure, as explained in the case of the medium content
was used to obtain the collagen amount. The total amount of collagen obtained was
divided by initial dry weights of the specimen to obtain the collagen content per unit mass
of specimen. These masses were plotted against respective portions of the scaffold.

6.4.2.7 Immunohistochemistry
CD31 Immunostaining
The α-smooth muscle actin staining was performed at University Pathology
Services, Wayne state University, Michigan. Sections were deparaffinized for CD31
immunostaining. The endogenous peroxidase was satiated by incubating the slides in 50
ml methanol, 0.5 ml H2O2 (30%) solution for 30 minutes. Trypsinization for 20 minutes at
37°C was used for antigen retrieval. Once the antigen was retrieved, the slides were preincubated with normal goat serum for 30 minutes. The primary antibody CD31 [188, 221-
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223] at a dilution of 1:10 was incubated overnight at 4°C. The secondary antibody was a
biotin-conjugated goat anti-rat polyclonal IgG. It was used at a dilution of 1:75.
Chromogenic

visualization

was

accomplished

using

a

streptavidin–horseradish

peroxidase conjugate, followed by diaminobenzidine substrate. The sections were
counterstained with Carrazi Hematoxylin.

6.5 RESULTS
6.5.1 Bioreactor Design
The bioreactor designed is versatile in its applications and compact in design. The
materials used offer outstanding dimensional stability and autoclavability. It consists of a
bubble trap/compliance chamber, two culture chambers and a reservoir. The volume in
the bubble trap is ~200 ml while that of the culture chambers is 100 ml each. Alterations
of the design can allow incorporation of multiple constructs. The entire bioreactor system
has the same diameter tubing throughout and thus no backpressures generation was
encountered. Pulsation was introduced into the system to mimic the physiological
conditions of the aorta by adjusting the flow rates and beat rate.

6.5.1 Cell Viability
The assay exhibited the presence of live cells in the vascular graft (see Figure 6.2
and 6.3). The results presented here are only for bioreactor II and III, since for bioreactor
I a different viability assay was used which did not give any conclusive results.
In the case of Bioreactor II, the amount of cells present on the luminal surface of the graft
increased from the second day of culture and continued to increase through the second
week of culture. There was no obvious alignment of cells on the luminal surface. Similar
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behavior was observed in bioreactor III. Cells increased in numbers and appeared to
cover the luminal side of the surface after two weeks of culture.
Bioreactor II

Day 7

Day 13

Figure 6.2 Live-dead assay conducted on portions of the vascular graft grown in Bioreactor II at
day 7, 13. The red areas indicated the number of live cells.

Bioreactor III

Day 5

Day 14

Figure 6.3 Live-dead assay conducted on vascular graft portions of the scaffold grown in
Bioreactor III at day 5, 14. The red areas indicated the number of live cells.
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6.5.2 Histology
The histological examination (Hematoxylin and Eosin stain and Mason’s
Trichrome) are presented in figure 6.4, 6.5 and 6.6. This analysis was performed to
evaluate cellular alignment as well as the degree of cell penetration within the scaffold.
In the case of construct grown in bioreactor I, the smooth muscle cells penetrated the
scaffold in a non-homogeneous distribution across the surface and thickness of the
construct.
For bioreactor II, smooth muscle cells penetrated the scaffold individually but
seemed to have grown in clusters. The largest amounts of clusters were detected mostly
at the luminal surface on day 7. As the culture progresses, the cells migrated inward. On
day 14, cells are present about 300 µm into the scaffold.
For bioreactor III, the presence of the endothelial cell layer seeded after the
smooth muscle cells increased the penetration and cell distribution. Both SMCs and ECs
seemed to attach and grow. The EC-SMC interactions can control cellular growth,
migration, differentiation. The bidirectional cross talk between EC and SMC may
influence EC responses to hemodynamic forces.
Based on earlier studies of cell seeding, the higher cell retention and proliferation
could be attributed to the could be attributed to the collagen gel seeding method as
explained in Chapter 5 and pulsatile flow conditions of the bioreactor. Pulsatile flow has
an impact on cell morphology proliferation and composition of extracellular matrix.
In addition to Hematoxylin-Eosin stain, we used Mason’s trichrome stain, which
detects presence of collagen for all the bioreactors to determine the rate of collagen
production within the tissue. The results indicate that visible collagen was mainly
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observed in cell clusters. A potential cause of this could be that the cells contracted the
collagen gel used for seeding and insufficient collagen was generated over the culture
duration to allow detection.

Lumen

Bioreactor I

Day 11

120

Lumen

Day 7

Day 20
(a)

Lumen
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Day 20
(b)
Figure 6.4 Histology analysis conducted on vascular graft grown in bioreactor I. (a) H&E stain for
day 7, 11 and 30 (b) Mason’s trichrome stain for day 20. For H & E stain, the purple portions
correspond to the cells, and the pink/red represents the chitosan material. For Trichrome staining,
the red corresponds to the material, blue for the collagen and brownish represents the cells.
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Lumen

Bioreactor II

Lumen

Day 7

Day 7

(a)

Lumen
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Lumen

Day 13

Day 13

(b)

124

Lumen

Day 7

Day 7

(c)
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Day 13

(d)
Figure 6.5 Histology analysis conducted on vascular graft grown in bioreactor II. (a) H&E of day 7
of culture; (b) H &E of day 13 of culture; (c) Mason’s trichrome stain of day 7; (d) Mason’s
trichrome stain of day 13. For H & E stain, the purple portions correspond to the cells, and the
pink/red represents the chitosan material. For Trichrome staining, the red corresponds to the
material, blue for the collagen and brownish represents the cells.
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Lumen

Bioreactor III

Day 5

Day 5
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(a)

Day 5

Lumen

(a)

Day 14
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Day 14

Day 14
(b)
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Day 14

(c)
Figure 6.6 Histology analysis conducted on vascular graft grown in bioreactor III. (a) H& E stain at
day 5 of culture; (b) H & E stain at day 14 of culture; (c) Mason’s trichrome at day 14 of culture. For
H & E stain, the purple portions correspond to the cells, and the pink/red represents the chitosan
material. For Trichrome staining, the red corresponds to the material, blue for the collagen and
brownish represents the cells.
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6.5.3 Collagen Quantification
A standard curve of known hydroxyproline content was established. The curve
exhibits a linear correlation between the standard hydroxyproline content and the
spectrophotometric absorbance values at 560 nm (Figure 6.7).

Figure 6.7 Standard curves for 4-Hydroxyproline content.

Hence there was no collagen visible in Mason’s trichrome strain for bioreactor I, the
collagen content was determined only for bioreactor II and III.
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Figure 6.8 Cumulative collagen content present in the constructs obtained: (a) medium ;(b)
bioreactor at regular intervals. The amount of collagen in the medium was determined by first
evaluating the hydroxyproline utilizing the equation in 6.7.
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Comparison of medium samples obtained from Bioreactor II exhibited an increase
from day 0 to day 7, after which a narrow decrease until day 14. For bioreactor III, the
collagen exhibited an increase in collagen amount with increase in time. A sharp
increase can be distinguished after day 5 up to day 14.
The collagen content per unit mass of the tissue construct grown in bioreactor II
exhibited a higher amount of collagen than bioreactor III. In the presence of endothelial
cells, the collagen amount produced within the construct was lower.

6.5.4 Immunohistochemistry
Immunohistochemistry refers to the procedure of localizing antigens in cells of a tissue
section-utilizing antibody binding to antigens in the tissue.CD31 is a marker for mature
endothelial cells.. The CD31 analysis of the fixed tissue samples indicates presence of
endothelial cell within the structure. Meanwhile in bioreactor III we had a mixture of
SMCs and ECs therefore we used this technique to detect the presence of CD31
markers. The assay was confirms the presence of endothelial cells into the scaffold.
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(a)

(b)
Figure 6.9 Expression of SMC and EC markers for day 14. (a) Control of an aortic tissue; (b) CD31
expression in SMC-EC seeded scaffold.
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6.6 DISCUSSION
Evaluation of cultured constructs was critical for any tissue-engineered graft
because it provides information concerning tissue regeneration, cell arrangement,
distribution, viability and extracellular matrix. In the present study, experiments were
performed to evaluate the presence of live cells, distribution and generation of
extracellular matrix in the construct.
Literature suggests that combining retinoic acid and ascorbic acid resulted in
enhanced collagen and elastin production with enhanced mechanical strength and
stiffness [224]. As a result, these ECM proteins were added to the medium composition
because they contribute to matrix deposition.
In case of the bioreactors I, II and III, cell seeding was conducted in a CM
dextran sulfate dry scaffold for 20 min using a cell-collagen suspension, gelation time
was under an hour.
However, eliminating collagen from scaffold material and adding it to the seeding
technique resulted in an increase of cellular attachment. At the same time, addition of
endothelial cells after initial SMCs seeding appeared to increase cell viability and
distribution.
The evaluation of the constructed established the presence of live cells, cellular
retention, distribution and collagen content. The H&E staining showed to what degree
the cells penetrate the scaffold. At the time of seeding, individual cells are present within
the scaffold. As the culture time passes and the cells were exposed to pulsatile flow,
cells migrate toward the luminal side where nutrient transport is more efficient.
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Differences in collagen amount between the two tissue cultures reported were very
small. This could be partly because there was very low amount f collagen produced in
the weeks of culture or most of the collagen leaked out from the tissue into the medium.
The current seeding method as well as culture conditions has provided valuable
insights into how efficient the chitosan-GAG performs in-vitro. The constructs exhibited
differences in the cell attachment because of number of cells seeded, type of flow and
whether SMCs were seeded separately or in the presence of endothelial cells. These
variations were confirmed by live dead assay, histology and hydroxyproline assay.

6.7 RECOMMENDATIONS
Even though, the addition of collagen gel improves vascular cell distribution, it is
anticipated that using a dynamic collagen seeding method can improve the attachment,
distribution and proliferation of cells. Higher density of cells with enough volume to fill
the scaffold should be used in order to facilitate adhesion. Consequently, an increase in
flow rates would be used to help cellular arrangement, proliferation and increase in ECM
production. The manner by which cells are incorporated can be important determinant
and needs to be examined further. A dynamic collagen gel seeding device might be able
to resolve the problems currently observed with the static collagen gel techqniue. Hence,
under normal static conditions cells have the potential to de-differentiate which in turn
leads to loss of cell function. Longer time cultures within the bioreactor are needed
because it is an indication of tissue generation and cell attachment and viability.

137

Chapter 7
OVERALL CONCLUSIONS AND FUTURE WORK

7.1 OVERALL CONCLUSIONS
Congenital heart and large vessel defects are a significant cause of morbidity and
mortality in pediatric patients. Current vessel replacement options lack the capacity to
grow and remodel in response to patient needs. This limitation is a major problem for
pediatric patients who may require multiple surgical procedures before reaching
adulthood.
For developing a vascular graft, scaffold material biological and mechanical
properties are very important. The 2-D studies indicated that chitosan surfaces
crosslinked with carboxymethyl dextran sulfate causes an increase in SMCs attachment
and proliferation. Carboxymethylated dextran sulfate chitosan was an excellent base
material for SMC colonization.
We explored the prospect of a tissue engineered large vessel graft using
polysaccharide biomaterials. Our scaffold design was based on the use of chitosan as
the main structural biopolymer, with cell adhesion; ligands provided by seeding cells with
Type I collagen. In addition, we explored the effects of covalently grafting various
glycosaminoglycans to the scaffold surfaces to promote binding and presentation of
growth factors and extracellular matrix proteins. At the same time, it was observed that a
chitosan scaffold exhibited a better porosity than a chitosan-collagen scaffold, which in
turn allowed for enhanced cell-collagen gel seeding. From scaffolding point of view, a
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chitosan material seeded with collagen gel was selected as a feasible material
composition for the graft construct.
The bioreactor design indicated that SMC cells attach to the vascular scaffold.
However, more improvement is required to create a functional graft. The comparison
between bioreactor I, II, III indicated that when using a co-culture of SMCs with ECs, we
achieved better penetration, attachment and viability.

7.2

RECOMMENDATIONS

The overall research work was the attempt to generate a GAG-chitosan tissue
engineered vascular graft. There was reasonable success; substantial amount of
research should be done to get the project to the next step in-vivo studies. Some of the
critical changes as future research that is required are as follows:
1. Medium formulation- Optimal concentration of AA and RA needs to be evaluated
hence these play a role in ECM production. Addition of PDGF and TGF-β should
be considered.
2. Bioreactor Design: Substantial modification to the current system is required to
make it convenient to run 4-5 cultures at the same time as well as make it efficient
for pulsatile pressure and flow conditions. This could be used to compare various
materials as well as being able to sacrifice an entire scaffold at various time
points. The bioreactor should be run for 2-3 months for one study.
3. Cell isolation: A potential source for SMC’s in the vascular graft construction can
be using bone marrow mesenchymal stem cells (MSCs). Ex-vivo expanded stem
cells have been known to cause very low immune response in-vivo. MSC’s have
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considerable plasticity. They have been known to differentiate into fat, muscle and
connective tissue [225-230].
4. Scaffold materials: Our scaffold material contains only chitosan. For better
mechanical properties, elastin fibers could potentially be included into the
structure. This would enhance the elasticity of the structure. Apart from this,
further studies are required for chitosan crosslinked with chondroitin 4 and 6,
since they are the most abundant found in aorta.
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According to the World Heart Organization, cardiovascular diseases claim 17.1
million lives each year, from which congenital heart defects account for 26%. As the
most frequent congenital anomaly and the leading cause of death, congenital heart
disease is an attractive target for tissue engineering research. New drugs and innovative
devices have improved the quality of life for pediatric patients with congenital heart
defects, but have not necessarily decreased the morbidity and mortality. The challenging
target to engineer a native blood vessel stems from the need to find substitutes for
pediatric patients born with congenital defects. With the advances in the fields of
biomaterials and tissue engineering, scientists have been exploring the use of synthetic
non-degradable, synthetic resorbable, natural polymers and completely cell based
approach. Some of the approaches take advantage of materials such as collagen or use
of natural components in synthetic materials.
One promising alternative involves using a tissue-engineered graft. The tissue
engineering graft functions to bring various cells of the vasculature in close proximity to
one another to enable intercellular signaling which facilitates cell adhesion, migration and
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differentiation. Using the classical tissue-engineering paradigm, autologous cells are
seeded on a tubular scaffold, which provides surfaces for cell attachment and space for
neotissue formation. The ideal graft requires a range of characteristics including
strength, biocompatibility, biostability and ability to adapt to the hemodynamic conditions
in the short and long term.
A number of various GAG materials were investigated in this dissertation and
various scaffold and bioreactor design. And it was concluded that carboxymethylated
dextran sulfate chitosan was an excellent base material for SMC and EC colonization as
well as use in vascular graft material. The 3D in vitro studies indicated that the material
had promising results for development of a tissue engineered vascular graft.
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